



Hôpital général juif
Jewish General Hospital

DEPARTMENT OF MEDICINE

ANNUAL REPORT

January 1 - December 31, 2019

**Submitted by
Dr. Ernesto L. Schiffrin
Physician-in-Chief**

DEPARTMENT OF MEDICINE - JEWISH GENERAL HOSPITAL

January 1 - December 31, 2019

TABLE OF CONTENTS

1. **ACADEMIC HIGHLIGHTS / OBJECTIVE AND PRIORITIES**
2. **GRAND MEDICAL ROUNDS & INVITED SPEAKERS**
3. **UNDERGRADUATE AND POSTGRADUATE TEACHING REPORTS**
4. **EXTERNAL RESEARCH GRANTS & AWARDS**
5. **NEW HONORS, AWARDS AND APPOINTMENTS**
(SEE APPENDIX A)
6. **PUBLICATIONS**
7. **APPENDIX A. DIVISIONAL REPORTS**

1. **Division of Allergy and Clinical Immunology**
2. **Division of Cardiology**
3. **Division of Dermatology**
4. **Division of Endocrinology**
5. **Division of Gastroenterology**
6. **Division of Geriatric Medicine**
7. **Division of Medical Genetics**
8. **Division of Hematology**
9. **Division of Infectious Diseases**
10. **Division of Internal Medicine**
11. **Division of Medical Biochemistry**
12. **Division of Nephrology**
13. **Division of Pulmonary Medicine**
14. **Division of Rheumatology**
15. **Division of Clinical Epidemiology**

Not included, non-traditional divisions only recently incorporated to the Department

16. **Division of Critical Care Medicine**
17. **Division of Medical Oncology**
18. **Division of Neurology**
19. **Division of Pathology**
20. **Physiatry**
21. **Division of Radiation Oncology**

1. ACADEMIC HIGHLIGHTS / OBJECTIVE AND PRIORITIES

1.1 ACADEMIC HIGHLIGHTS

I. Introduction

The current report includes the divisions of Allergy & Clinical Immunology, Cardiology, Clinical Epidemiology, Dermatology, Endocrinology, Gastroenterology, Geriatric Medicine, Hematology, Infectious Diseases, Internal Medicine, Medical Biochemistry, Nephrology, Pulmonary Medicine, and Rheumatology. It does not cover the activities of Critical Care Medicine, Medical Genetics, Medical Oncology, Neurology, Pathology, Physiatry and Radiation Oncology, that were added as divisions of the Department of Medicine by the Quebec Ministry of Health or in the case of Pathology, by the Director of Professional Services after creation of OPTILAB.

The Department continues to provide excellent clinical care and teaching as well as carry out substantial translational, clinical and epidemiological research that attracts new recruits to the JGH. Although recruitment is limited by government restrictions of the “effectifs médicaux”, we have managed to recruit during the year January 1 to December 31, 2019, six (6) full-time members and two (2) associate members. Potential and confirmed recruits as well as changes in staffing are listed below.

Our research activities have been supported by both external funding agencies and by our own Clinical Research Awards.

The progress and challenges of the Department during this last academic year are summarized below.

II. Milestones

A. Recruits

The following physicians have been recruited in 2019 and beyond into the Department:

2019-

GFT members:

Cardiology - Dr. Nathan Messas (October 2019)
Cardiology - Dr. Maude Peretz-Larochelle (July 2020)
Dermatology - Dr. Philippe Lefrançois (August 2021)
Endocrinology - Dr. Vincent Larouche (July 2019)
Endocrinology - Dr. Jill Pancer (July 2020)
Gastroenterology - Dr. Chiara Saroli Palumbo (July 2019)
Geriatric Medicine - Dr. Cyrille Launey (February 2020)
Hematology - Dr. Rayan Kaedbey (October 2019)
Infectious Diseases - Dr. Ling Yuan Kong (July 2019)
Infectious Diseases - Dr. Catherine Hogan - (July 2020)
Internal Medicine - Dr. Teresa Cafaro (November 2020)
Nephrology - Dr. Daniel Blum (July 2019)
Pulmonary - Dr. Nan Zhao (September 2020)
Rheumatology - Dr. Sophie Wocjik (July 2020)

Associate members:

Cardiology - Dr. Nicolo Piazza (September 2020)
Gastroenterology - Dr. Constantine Soulellis (February 2019)
Hematology - Dr. Marc Rodger (January 2020)
Medical Genetics - Dr. Thomas Kitzler (July 2019)
Medical Oncology - Dr. Khashayar Esfahani (January 2020)

B. Changes of Status

GFT members resigned:
Endocrinology - Dr. Alicia Schiffrin (June 30, 2019)

In memoriam:

Dr. Prem Ponka passed away suddenly on November 3, 2019 while attending a conference in Paris.

C. Promotions

Stéphanie Lehoux, PhD, based at the Lady Davis Institute, in the Division of Cardiology, was promoted to Full Professor with tenure. Dr. Lehoux directs a research program in mechanotransduction and vascular biology. Her work is relevant to understanding the mechanisms underlying the vascular remodeling associated with hypertension and atherosclerosis.

Kristian Filion, PhD, based at the Jewish General Hospital in the Division of Clinical Epidemiology, was promoted to Associate Professor with tenure. Dr. Filion's research interests include pharmacoepidemiology and drug safety, knowledge synthesis, and cardiovascular epidemiology.

III. Clinical Activities

The CTUs on K6 and K7 have been downsized to 28 bed units instead of 32. This smaller number is more in line with other CTUs both at McGill and across the country. In order to achieve this lower census, an 8-bed Hematology unit was created on K7 staffed by hematologists.

The transition to the new bed distribution on the KTCs has been successful. The 8-bed hematology unit is functioning smoothly on K7 with the help of two excellent nurse practitioners. That leaves 24 beds on K7 for the CTU team who also look after 4 beds on K6 for a total of 28 beds per CTU. This census can be exceeded when patients are doubled up in rooms when a state of Overcapacity 1 or 2 are declared by the hospital, or with an occasional off-service patient, i.e. on K8, for example, where CRO patients are cohorted.

The volume of turnover of patients on the medical CTUs continues to be high and 4-6 discharges per day are routine and the number can spike to as high as 7 or 8 per day.

In the ER, the Internal Medicine team in the CTU in ER (ERC) continues to be inundated with consults from the ER. Typically, there is an average of 11-13 patients each morning waiting to be admitted, sometimes during the year up to 25 patients will be under the care of the ERC team. The overall total of admission from the ER including all services averages 27-30 per day, of which 50%, sometime more, are Medicine admissions, mostly to Internal Medicine units, either the CTUs on K6 and K7, or the non-teaching unit on CD7, or off-service.

The hand washing reports continue to underscore that there is room for improvement. The global stats for the hospital showed a decline from 75-67 percent over the last few months (target 80%). Physicians, residents, and medical students all typically score similarly in the 53-74% range. This is similar to unit agents but well behind physiotherapists, occupational therapists, dieticians, and pharmacists but happily above transport attendants who score 28-30%.

The Diagnostic and Treatment Clinic (DTC) located in the Medical Day Hospital is running 3 days/week, although plans are underway to staff this clinic 5 days per week in the near future. The volume is steady with the clinic receiving 60-80 patient visits per month. Members of our department regularly consider the option of referring ambulatory patients to the DTC for expedited investigation and management as an alternative to contributing to overcrowding of the ER.

The clinical activities of the individual Divisions are summarized in the attached Divisional reports.

IV. Teaching Activities

The Department continues its role in the teaching of both undergraduate medical students and resident physicians in

general medicine and the subspecialties. Our members' dedication to teaching is well known and much appreciated by both medical students and residents. The Department is grateful to Dr. Ruxandra Bunea, who stepped down as site director of the residency program in Internal Medicine in July 2019, her replacement, Dr. Elise Levinoff, and Dr. Nathalie Saad, side director for the undergraduate training program, for their excellent contribution to our postgraduate and undergraduate teaching programs.

The Department is deeply appreciative of **Dr. Ruxandra Bunea's** dedicated services for the past 8 years (July 2011 to June 2019), her leadership and being a role model for residents, and for having effectively and smoothly incorporated changes within the residency program while maintaining a cordial relationship with residents, contributing thus to an excellent educational environment. **Dr. Elise Levinoff**, Assistant Professor in the Division of Geriatrics, was been appointed as JGH Site Director for the Core Internal Medicine Residency Training Program effective July 1, 2019.

In 2019-2020 we recruited into our teaching program 13 R3, 16 R2, and 16 R1 housestaff and 8 other program R1 residents. There are three Chief Residents, **Dr. Anthony Lieu, Dr. Jordan Mah and Dr. Marc-Alexandre Gingras** (July 2019-June 2020). Detailed reports of the undergraduate and postgraduate teaching are included below.

At the undergraduate level, **Dr. Nathalie Saad** has been appointed to the positions of Chair of Undergraduate Medical Education within the Department of Medicine, Director of Clerkship for the Department of Medicine and Director of Transition to Clinical Practice for the Department of Medicine, since August 1, 2018. She continues in her role as Site Clerkship Director at the JGH. She was also recently elected to the Board of the Collège des médecins du Québec.

Dr. Jason Agulnik, who has been active in teaching medical students and residents for a number of years, continues as Site Director for Transition to Clinical Practice at the Jewish General Hospital.

Dr. Maral Koolian continues as Program Director of McGill University's new AFC (Area of Focused Competence) in Adult Thrombosis Medicine. Adult Thrombosis Medicine is that area of enhanced competence within Medicine concerned with the investigation, diagnosis, and medical management of patients with venous and arterial thromboembolic disease in a variety of clinical contexts.

Dr. Lorraine Chalifour, Associate Professor, Division of Experimental Medicine, continues as Associate Dean of Graduate and Postdoctoral Studies at McGill University.

Dr. Annabel Chen-Tournoux, Assistant Professor based at the JGH, has been reappointed as **McGill Cardiology Program Co-Director** effective July 1, 2019.

Grand Rounds: Of the 33 Grand Rounds given by the Department from January 1 to December 31, 2019 twelve (12) featured speakers from outside the JGH, of whom six (6) were from outside Quebec (see below list of rounds).

Divisional Rounds: In addition to the above each Division manages its own teaching and research rounds as summarized in the divisional reports.

V. Honours, awards and prizes

Within the Department, the following are noteworthy appointments and awards:

Dr. Gerald Batist, Professor of Medicine and Oncology, Director of the Segal Cancer Centre and of the McGill Centre for Translational Research in Cancer, received the **2019 Award for Exceptional Leadership in Cancer Research** from the **Canadian Cancer Research Alliance**.

Dr. William Foulkes has been honoured with the 2019 Distinguished Scientist Lecture and Award by the Canadian Society for Clinical Investigation for having made significant contributions to new knowledge for recognized in their field as expert, innovative, and in the forefront of research endeavors. He delivered his lecture at the CSCI Annual Meeting in Banff, Alberta.

Dr. Gad Friedman, Division of Gastroenterology, was honored at the Gala **for Crohn's and Colitis Canada 2019**

in Montreal for his excellent and innovative patient care. His contributions include the introduction of specialized techniques to our hospital such as removal of large polyps and common bile duct stones resulting in decreased need for surgery as well as the creation of an accredited McGill-wide nurses' education program in gastroenterology.

Dr. Christina Greenaway was included in the Canadian Society for International Health's first list of Canadian women leaders in global health. The list recognizes the achievements and expertise of women in global health.

Dr. Susan Kahn, Professor in the Division of General Internal Medicine, was selected as the **Clinical Research Scientist of the Year by the Lady Davis Institute** of the Jewish General Hospital. She was also appointed **Member of the Advisory Board for the CIHR's Institute of Circulatory and Respiratory Health** and added to the **Grands Noms de la Médecine au Québec**, Fédération des médecins spécialistes du Québec.

Dr. Ernesto L. Schiffrin received the **Distinguished James McGill Professor** award which recognizes a late-career scholar's sustained scholarship of world-class caliber, international leadership and outstanding research record.

Dr. Samy Suissa and **Dr. Wilson Miller** were also nominated as **Distinguished James McGill Professors**.

Residents' Awards

Dr. Nicolas Meti received the **Dave Feder Award**. This award is presented to the resident who practices medicine with most compassion and sensitivity, displays kindness, respect and camaraderie towards colleagues and educators and carries a positive outlook enabling him/her to enjoy a meaningful balanced life beyond his/her profession.

Dr. Camille Simard received the **Dr. Allen Spanier Internal Medicine Award**. This award is given to the resident who exhibits an enduring passion for the practice of medicine, through the enjoyment of solving challenges of patient care and sharing solutions with others, while maintaining a high level of professionalism.

Dr. Marc Nicolas Bienz was the recipients of the **Sheldon Zelman Memorial Award** given for academic excellence and outstanding contribution to patient care.

Dr. Khaled Isselmou was the recipient of **Fellow of the Year Award**. This award instituted in 2016 is given to the fellow in Internal Medicine or its sub-specialties who most significantly contributes to the training and formation of Jewish General Hospital Internal Medicine residents and inspires colleagues and juniors with his/her role-model clinical skills.

Dr. Maral Koolian was voted as **Teacher of the Year** by the residents. She also won the Internal Medicine TCP Teaching Award for her dedication to teaching history taking and physical exam skills during the Transition to Clinical Practice course.

VI. Research

The Department of Medicine research activities have been supported by both external funding agencies and by its own Clinical Research Awards, supported by endowment funds coming from the Doctor's Galas, and the Academic Excellence Award of the Auxiliary which is awarded every other year.

Department of Medicine Clinical Research Awards

The goal of this award is to contribute to the academic development of the Department, and to encourage full-time contract academic staff (CAS, previously called GFT-H) involved in clinical research by compensating, in part, their time dedicated to clinical research activities. The Research Advisory Research Advisory Committee reviewed applications based on quality of projects, role and productivity of applicant, likelihood of publication in a peer-reviewed scientific journal and awarded seven (7) new applicants, renewed six (6) previous applicants and granted an extra year to three (3) applicants. The support has increased from an original budget of \$40,000 in 2007 to \$239,000 in 2019. The amount of the award was increased from \$12,000 to \$15,000 per year starting May 2019.

Three awardees of this program, Drs. T. Jagoe, Dr. E. Levinoff and M. Teltscher, presented at Medical Grand Rounds on October 7, 2019. This was the Fifth Annual Clinical Research Symposium of the JGH Department of Medicine.

Research Funding

Total funding from external peer review granting agencies to JGH researchers in 2018-2019 was \$36,836,844 (Medicine \$26,593,657).

Salary award funding

For the period 2019-2020, 9 Departmental members are holding prestigious Career Awards, Fellowship Awards or Research Chairs from various granting agencies, totaling \$525,468. All clinical researchers are strongly encouraged to apply for salary support awards, as during the tenure of their awards, successful candidates can benefit from the generous RAMQ Clinical Researcher salary compensation program.

In 2019, Dr. François Mercier received an FRQS grant as well as salary award. Drs. Mark Eisenberg, Marie Hudson, Chen Liang, Koren Mann and Chantal Autexier, Stephanie Lehoux, Andrew Moulard, Brent Richards, Brett Thombs and Mark Trifiro received CIHR operating grants in 2019.

McGill University Department of Medicine Research Symposium

McGill University Department of Medicine Research Symposium took place on April 24, 2019 at the McGill New Residence Hall and featured two outstanding keynote speakers and four speakers from the Jewish General Hospital, Drs. A. Gatignol, A. Karaplis, S. Kahn and F. Mercier with Dr. E. Schiffrin providing the closing remarks.

Publications

The number of publications authored by members of the Department of Medicine was 401 in 2019.

VII. Departmental Activities

The Department continues to reinforce democratic and transparent management in all areas.

VIII. MUHC and McGill

Our relationship with the MUHC has been characterized by collaboration and collegiality. Our commitment to excellence in teaching at both the undergraduate and postgraduate level continues to be valued by McGill University.

The Department continues to work towards maintaining its academic mission with improved staffing and resource allocation.

The Department gratefully recognizes the support of the University and Hospital Administration in its recruitment efforts.

1.2 OBJECTIVES AND PRIORITIES

The Department of Medicine continues to play a key national and international role with many members active across Canada and in the international academic arena.

We remain dedicated to ensure that the department continues to provide excellent care to the patients of the

hospital for which it is renowned, while at the same time maintaining its goals of excellence in teaching. The recruitment of highly qualified and competitive physician scientists has reinforced the research capacity of the department and has had a transformative effect on the ability of the hospital to serve as a translational science center. It has been challenging to provide conditions that are competitive with the best North American centers due to constraints in funding for personal support, operating monies and up-to-date equipment, as well as difficulties in ensuring adequate space allocation and support services. Despite these difficulties and constraints, we have been successful as can be seen above in already recruiting or about to recruit a considerable group of young physician-educators and physician-scientists in the areas of internal medicine, cardiology, endocrinology, hematology, pulmonary medicine, rheumatology and nephrology, all of who have a good chance of success in scientific competition for the scarce resources currently available locally, provincially and nationally. We have continued to fund and enhance a program that helps support the research by contract academic staff (CAS, previously called GFT-H) physicians.

Respectfully submitted,

Ernesto L. Schiffrin, C.M., MD, PhD, FRSC, FRCPC, FACP
Physician-in-Chief

MEDICAL GRAND ROUNDS & INVITED SPEAKERS (January 1 - December 31, 2019)

| | | |
|--------------|---|--|
| January 7 | Polygenic Risk Scores to Predict Clinical Outcomes | Brent Richards, MD |
| January 14 | Time to move on – from 9H to 4R: shorter, safer, cheaper and better Results of two randomized trials in adults and children, of 4 months Rifampin (4R) vs 9 months Isoniazid (9H) for treatment of latent TB | Richard Menzies, MD, MUHC |
| January 21 | An Epidemiological Analysis of the Medical Literature: Lessons Learned from an Accidental Career in Medical Journalism | Christopher Labos, MDCM, MSc, MUHC |
| January 28 | Thirtieth Annual Humanization of Care Awareness Program Rounds: Keeping it Together When Everyone Around You Is Falling Apart | Susan Wener |
| February 4 | Fourth Annual McGill Global Health Initiative in Haiti Lectureshipan Impactful and Longitudinal Experience | Tanya Girard, MD IM Resident MUHC- McGill Jonathan-Houle, MD, Hematology Fellow McGill |
| February 11 | Cancer Associated Venous Thromboembolism: New Anticoagulant Therapeutics | Vicky Tagalakis, MD, MSc |
| February 18 | Thrombotic Microangiopathy (TMA) – Importance of the Differential Diagnosis: How Classification Impacts Investigations and Management | Louis-Philippe Girard, MD, Calgary University |
| February 25 | Ketogenic Diet and Diabetes: Why the Resistance? | Elizabeth MacNamara, MD |
| March 4 | Optimum Diet for a Long & Useful Life: What's the Evidence? | L. John Hoffer, MD, PhD |
| March 11 | Emergency Room and Older Patients: to be Frail or at Risk? | Olivier Beauchet, MD, PhD |
| March 18 | Uncommon Mechanisms in Thrombosis Research that Could Change your Practice | Ed Conway, MD, PhD, University of British Columbia |
| March 25 | New Drugs for the Treatment of Severe Asthma | Pierre Ernst, MD, MSc |
| April 1 | Lumps, Bumps and Genes | William D. Foulkes, MD, PhD, Maria Apellaniz-Ruiz, PhD & Barbara Rivera, PhD |
| April 8 | Modern Management of Chronic Thromboembolic Pulmonary Hypertension: JGH's Comprehensive Integrated Program - from Bench to Bedside to Operating Room or to Cath Lab | David Langleben, MD, Andrew Hirsch, MD, Jean-François Morin, MD & Ali Abualsaud, MD |
| April 15 | Penicillin Allergy | Jesse Schwartz, MD |
| April 29 | 2018 Louis and Arthur Lucian Award for Research in Circulatory Diseases Recipient's Presentation: Understanding and Managing Variable Drug Actions: from the ECG to Population Genomics (Chapter 2: the Cardiac Sodium Channel) | Dan M. Roden, MDCM, Vanderbilt University |
| May 6 | Cardiac Amyloidosis: the Mystery "Unfolds" | Michael Chetrit MD, Cleveland, Ohio |
| May 13 | Autoimmune Inflammatory Myopathies: How Extra Muscular Features Are Stealing the Show | Valerie Leclair, MD |
| May 27 | 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases Recipient's Presentation: From Secretory Precursor Proteins to the Discovery of the Family of Proprotein Convertases and Their Clinical Applications | Nabil G. Seidah, PhD, Université de Montréal |
| June 3 | The Work-up and Treatment of Cancer of Unknown Primary | Lawrence Panasci, MD |
| June 10 | Evolving Paradigms in the Clinical Care and Treatment of Hemoglobinopathies | Véronique Naessens, MD, MUHC |
| September 9 | Special Event: Meet and Greet the Residents | Elise Levinoff, MD |
| September 16 | Clinical Ethics Rounds: Ethical Issues Regarding Peg Feeding Tubes for Dementia Patients: a Case Review | Mr. Kevin Hayes, Clinical Ethicist & Albert Cohen, MD |
| September 23 | The Future of Pathology: Facts, Trends, and Dreams | Alan Spatz, MD |
| October 7 | Fifth Annual Department of Medicine Clinical Research Symposium: I. An Assay to Measure CYP3A4 and CYP1A2 Enzyme Activity in Humans: Potential Relevance in Lung Cancer II. A Multi-disciplinary Approach to Documentation of Delirium in Hospitalized Medical Patients III. Unusual Hobbies and Bad Habits: My Experience with Fecal Microbiota Transplant at the JGH | Thomas Jagoe, MD, PhD Elise Levinoff, MD Marty Teltscher, MDCM |
| October 21 | Cleanliness and Godliness: Revisiting Skin Hygiene and Cutaneous T Cell Dysregulation in Atopic Dermatitis | Carolyn Jack, MD, MUHC |
| October 28 | Dilemmas in the Care of the Person with Advanced Dementia | Susan Mitchell, MD, MPH, Harvard |
| November 4 | Recent Advances and Novel Approaches in Targeted Therapy for Lung Cancer | Carmela Pepe, MD & Jason Agulnik, MD |
| November 11 | Canadian Patient Safety Week: Improving Disclosure in Person Centered Care | Suzanne Levitz, MD, Mrs. C. Bellerose, Me N. Lecoq, Ms. I. Caron, & Mr. E. Liitwin Rayan Kaedbey, MD |
| November 18 | Multiple Myeloma: 2019 and Beyond | Averell Sherker, MD, Bethesda, Maryland |
| November 25 | Can We Eliminate Hepatitis C? | Daniel Roy, MD, CHUM - Université de Montréal |
| December 2 | The Journey of Endovascular Treatment in Acute Stroke: Where Are We Coming From, Where We Are Now, Where We Are Going | Mark Trifiro, MD |
| December 9 | Nano-medicine - the Future Is Here | Alexander Thiel, MD, PhD |
| December 16 | Inflammation after Stroke: a Treatable Mechanism of Cognitive Impairment? | |

3. UNDERGRADUATE AND POSTGRADUATE TEACHING REPORTS

A. REPORT OF UNDERGRADUATE TEACHING - DECEMBER 2019

There continues to be exciting progress in the undergraduate education program.

1. RAC (Review/Assess/Consolidate)

There were 33 RAC students. RAC is tutor-based teaching of physical exams paired with a Resident and consists of seven 1½ hours the 1st week, 3 hours the 2nd week plus 5 hours of OSCE from December 2 to December 13. All tutors have been found and the course started on December 2.

2. Transition to Clinical Practice (TCP)

From January - June 19, 2019, there were 53 TCP students.

For January 6 - June 19, 2020, there will be 55 TCP students (4-5/group) within an 8 week block. During the 1st & the last week of the 8-week course, there will be a rotation in Radiation Oncology with a block of 7 continuous weeks of internal medicine and a minimum of 48 hours of bedside teaching (6-9 hours per week) spread over 8 weeks. Academic half-days are scheduled for Wednesdays pm, Thursdays am and Fridays am. Recruitment of tutors presents challenges especially for Block 2 (March 2 - April 24, 2020)

Remuneration for teaching activities is paid by RAMQ. It is recommended that tutors keep a copy of their teaching schedule in case of an audit from the RAMQ.

Upcoming Workload Policy

Work week is not to exceed 50 hours (excluding evening and/or weekend scheduled activities) with a maximum of 70 hours weekly when clinical, academic, examination activities are included.

Work day (including scheduled evening activities) must not exceed 16 hours. Students must have a minimum of 8 hours in between the evening activity and the start of a morning activity

Upcoming Changes

The EPA form will replace the observed bedside encounter (oral exam) evaluation form that will be sent to the Faculty as proof of completion of the activity.

Changes to the Passport

Attendance to the Interdisciplinary rounds is now a mandatory activity. The paper version will still require tutor's signature.

3. Clerkship Structure

The current structure has the medical students doing 4 weeks of either K6 or K7, 2 weeks of CVU/CVICU, 2 weeks of ER Consults.

Evaluation Forms

Evaluation of students by Attending MUST be completed within 2 weeks from the end of the rotation.

Entrustable Professional Activity 1 (EPA 1) Form

A total of 2 EPA's need to be observed on K6 & K7. Attending will observe the students perform an activity at the bedside, with the-week-1-2-attending expected to observe the student take a focus history and the-week-3-4-attending, the focus physical exam.

The student will arrange and inform the Attending of a time that is convenient for them, when the observed encounter will take place. Students are responsible for forwarding the EPA form to be filled in (the form will be in the Attending's ONE45 inbox)

4. Student with Academic Difficulties

Attendings should inform by email the Undergraduate Office as soon as possible if/when a student is having difficulties. A "borderline" or "fail" mark cannot be given to a student without informing the Undergraduate Office. The JGH Site Director usually meets and works with the student to address the concerns.

Students' absence from the floor

A student's absence on the floor without an email notification from the site administrator, should be reported as soon as possible. Students must return to the floor after their exam.

Workload policy

With the rapid turn-over, it is now more common to have students spend more than 10-12 hours/day on the ward. To respect the McGill workload policy, if possible, attendings should try to help by reviewing admissions before or at sign-out and ensure that admissions are assigned to the clerkship student before noon, if the student is not on a late shift until 20h00.

Upcoming Changes

There will be no sharing of the 16-week rotation with General Surgery. Students will complete 8 weeks of Internal Medicine back-to-back at the same site.

Along with the longitudinal exam, there will be an additional all-day exam including a progress test and a specialty exam on the last Friday of the 16-week block.

STAT Days

With the exception of Christmas & New Year, students will not be present in the Hospital. Weekend includes Monday STAT days and the Christmas/New Year period includes seven days off (5 weekdays & 2 weekends).

5. Elective Students

To protect patients, students, elective supervisors and avoid any institutional liability issues, all elective requests must go through the Faculty's web-site for approval.

The success of the UGME is due to the participation and dedication of all Divisional members of the Department of Medicine.

Respectfully submitted,

Nathalie Saad, MD, FRCPC, MBA

Site Director, Undergraduate Education, Internal Medicine, Jewish General Hospital

B. POSTGRADUATE TEACHING REPORT - DECEMBER 2019

Residents' Number

There were 16 incoming R1's, 16 R2's and 13 R1's in the 2019-20 academic year.

CaRMS 2020

The Internal Medicine Program at McGill University has been doing very well in CaRMS in the last 7 years, and this trend continues. All the spots at McGill University were filled in the first iteration in 2019. This year, there are over 400 applicants who will be screened for interviews. CaRMS interviews are in mid-January. We anticipate that there will be approximately 11-13 residents who will start at the JGH in July 2020 and a total of 39 incoming residents to the McGill Program. As always, thank you to all those who volunteer their time with applications and interviews.

Accreditation

The final accreditation report for the Internal Medicine Program was submitted by the Royal College of Physicians of Canada in October, 2019. The program's status is currently "Accredited with Notice of Intent to Withdraw Accreditation." There will be a review of the program in May, 2022, and there will be an internal review prior to this Royal College review. The program is working towards making improvements for the residents' learning environment, residents' wellness and teaching. There will be an upcoming PD retreat on December 4th, 2019.

Program Changes

Competence By Design

The major change within the program starting 2019 was the curriculum change to Competence By Design. Incoming residents are required to achieve certain milestones by completing entrustable professional activities (EPAs). To date, the R1s who began residency in July, 2019, have completed their first milestones which falls under Transition to Discipline. They are currently working through their Foundations of Discipline. The residents will ask attending staff to complete EPAs throughout their training experience and it is much appreciated if staff physicians can complete the EPAs on One45 as soon after the evaluation as possible.

CTU

The CTUs continue to consist of 28 patients, which is steady since July 2018. There is an 8 bed non-teaching Heme unit on K7, which is working very well. There are also 2 nurse practitioners rounding on the Heme unit. The staff and residents rounding on the CTUs have appreciated the decrease in the size of the CTUs, and all comments have been very positive. As usual, 2 admissions must be assigned by latest 10 am to juniors and students, so that the seniors can review 2 admissions before sign-out.

There has been ongoing discussion with regards to teaching on the unit. Initially, it was suggested there be a 20-30 minute teaching session every single day, on CTU. Staff must do a minimum of 2 teaching sessions in 2 weeks. In 2020, code blue rounds will be re-introduced to the teaching program. As well, we are hoping to involve the input of pharmacy to provide a teaching session to residents and students.

All residents must call the attending ward staff in the middle of the night if patients are being transferred to the ICU, CCU, code or die unexpectedly. This is in keeping with policies at the MGH and RVH.

Morning report will continue for the first 3 Fridays of the period, from 7:45 am to 8:30 am, and radiology rounds will continue every second Tuesday from 8 am to 9 am.

CCU

There is now a 20-bed non-teaching unit in CCU. This serves to reduce the size of the teaching CCU. The residents benefit greatly from the teaching experience that they receive on the CCU, and hopefully, this will continue.

Academic Half-Day

As of July, 2018, there are now 2 streams for Academic Half-Day: Thursday afternoons for R1s and R2s, and Wednesday mornings for R3s. The residents like this format so far. Residents are also attending academic half days at the McGill Simulation Centre, which they enjoy as well (crisis resource management, ethical scenarios, and procedure half days).

Royal College Exams

The R3s wrote their Royal College Exams in March and May, 2019. I am pleased to report that they have all been successful in passing their exams, and they are all now working through their fellowships in subspecialties. The major change for our site was the impact on schedule changes in March and May. Although there was a shortage of residents over this period of time, staff attendings filled the gaps while the residents were taking their exams. We have tried to change the master schedule so that there are 2 R2s on core rotations such as CTU, CCU, ICU, ERC.

Resident Research

Dr. Oriana Yu is our new JGH site Research Director. She has taken the time to meet with residents individually to review their projects with them to ensure that they are being completed on time. All residents must hand in an abstract and poster by June 30th of their third and final year of core internal medicine residency.

The clinical vignettes night were held on November 27th, 2019. Two speakers from the JGH were invited to present talks on interesting case reports. Dr Anthony Lieu won the Harold Frank Award.

IMGs

Originally, PGME was not going to accept sponsored residents from Saudi Arabia. More recently, it was decided that there will be residents from Saudi. However, this may prove to be difficult for 2020, and it will be a university wide decision as to whether Saudi Residents will be able to commence training in 2020 because of the last minute decision. If they will begin in July 2020, these incoming residents will also be required to complete a preliminary rotations for three months prior to starting residency called PEAP (Pre-entry assessment program) During these 3 months, the residents will carry a reduced number of patients similar to medical students and will not be able to sign orders until they officially begin residency on July 1st.

Other Varia

The residents lounge is currently being organized for the Internal medicine residents on the 6th floor. The residents would like to thank Dr. Schiffrin for facilitating this request.

Holiday Party

The Holiday Party was held on Sunday, December 8th, at 6pm, at Le Smoking Vallee. It was well attended by staff who took this opportunity to express their appreciation of the residents' contribution to the Department of Medicine.

Respectfully submitted,

Elise Levinoff, MD, MSc, FRCP(C)
JGH Site Internal Medicine Program Director, McGill University

GENERAL INTERNAL MEDICINE HOUSESTAFF LIST JULY 1, 2019 - JUNE 30, 2020

CHIEF RESIDENTS

Lieu, Anthony (July 1, 2019 - June 30, 2020)
Mah, Jordan (July 1, 2019 - June 30, 2020)
Gingras, Marc-Alexandre (July 1, 2019 - June 30, 2020)

R3

Akhtar, Muhammad (Haris)
Beltran-Bless, Anna-Alicia
Frohlich, Michael
Gingras, Marc-Alexandre
Krahn, Thomas
Lieu, Anthony
Mah, Jordan
Maheswaran, Janane
McConnell, Ted
Muhammad, Ajlan
Rabinovitch, Andrew
Rached-Dastous, Nour
Tsui, Harmony

R2

Ades, Matthew
Almazyad, Bader
Bedrouni, Wassim
Cotton, Thaisa
Dabaghjamanesh, Mojtaba
Deng, Lan
Di Iorio, Massimo Romolo
Elharram, Malik Mohamed
Escobar Olaya, Diana
Gerstein, Lindsey
Kazandjian, Suzanne (5-13)
Nodzynski, Thomas
Spillane, David
Tabah, Justin
Xiao, Yasi
Wright, Jennifer

R1

Alenezi, Talal
Alkhamees, Fatema
Almsarri, Qamar (SI)
Alqahtani, Mohammad
Belzile-Dugas, Ève
Kazandjian, Suzanne (Per 1-4)
Laverdure, Morgane
Makhaly, Samer
McPhaden, Heather
Miller, Adam
Negreanu, Daniel
Pang, Steph
Pavoni, Carolyn
Poirier Blanchette, Laurence
Rinfret, Félix
Sareen, Vasu

OTHER PROGRAMS

1st Year Residents Program Periods

Abdullah, Sarah Genetics (Periods 9-13)
Alhufayti, Ibtihal Genetics (Periods 9-13)
Al-Qahtani, Ahmed Ophthalmology (Periods 1-11)
Buyukkurt, Asli Neurology Periods 1-13
Oksenhendler, Rebecca Neurology Periods 1-13
Nanda, Rhaul Dermatology Periods 1-12
Saxena, Anjali Dermatology Periods 1-12
Desilets, Jade Obstetrics/Gynecology Per.2:
CTU; Per. 3: IMC

4. EXTERNAL RESEARCH GRANTS & AWARDS

A. Career Awards - July 2019 - June 2020 (Clinician-Scientists)

| Name | Agency | Expiry Date | Amount |
|-------------------|------------------------------|-----------------------------|------------------|
| AFILALO, Dr. J. | CIHR | 30-Jun-2022 | 60,000 |
| ASSOULINE, SARIT. | FRQS | 30-Jun-2022 | 39,913 |
| KAHN, Dr. S. | Tier 1 Canada Research Chair | 20-Sept-2021 | 120,000 |
| LONGTIN, Dr. Y. | FRQS | 30-Jun-2021 | 38,227 |
| MERCIER, Dr. F. | FRQS | 30-Jun-2023 | 35,393 |
| RICHARDS, B. | FRQS William Dawson | 30-Jun-2021 30-June-2020 | 38,227 15,000 |
| SCHIFFRIN, Dr. E. | Tier 1 Canada Research Chair | 31-Dec-2019 | 145,000 |
| YU, Dr. Oriana | FRQS | 30-Jun-2022 | 33,708 |
| TOTAL: | | | 525,468 |

B. Grants & Bursaries 2018-2019

See attached Excel File

5. NEW HONORS, AWARDS AND APPOINTMENTS (SEE APPENDIX A)

6. PUBLICATIONS (January - December 2019 - 401 publications)

Agulnik, Jason

--Wang H, **Agulnik J**, Kasymjanova G, Fiset PO, Camilleri-Broet S, Redpath M, Cohen V, Small D, Pepe C, Sakr L, Spatz A. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. *Lung Cancer*. 2019;132:36-38.

--Bebb DG, **Agulnik J**, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, Leighl NB, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS. Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective. *Curr Oncol*. 2019;26(4):e551-e557.

--Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, Spatz A, Rousseau C, McNamara S, Cohen V, **Batist G**, Agulnik J. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. *Mol Cancer Ther*. 2019 Sep;18(9):1628-1636.

Afilalo, Jonathan

--Galatas C, **Afilalo J**. Transcatheter aortic valve replacement over age 90: Risks vs benefits. *Clin Cardiol*. 2019 Dec 16. doi: 10.1002/clc.23310. [Epub ahead of print] Review.

--Damluji AA, Forman DE, van Diepen S, Alexander KP, Page RL 2nd, Hummel SL, Menon V, Katz JN, Albert NM, **Afilalo J**, Cohen MG. Older Adults in the Cardiac Intensive Care Unit: Factoring Geriatric Syndromes in the Management, Prognosis, and Process of Care: A Scientific Statement From the American Heart Association. *Circulation*. 2019 Dec 9;CIR0000000000000741. doi: 10.1161/CIR.0000000000000741. [Epub ahead of print].

--Asgar AW, Ouzounian M, Adams C, **Afilalo J**, Fremes S, Lauck S, Leipsic J, Piazza N, Rodes-Cabau J, Welsh R, Wijeyesundera HC, Webb JG. 2019 Canadian Cardiovascular Society Position Statement for Transcatheter Aortic Valve Implantation. *Can J Cardiol*. 2019 Nov;35(11):1437-1448. doi: 10.1016/j.cjca.2019.08.011.

--Goyal P, Gorodeski EZ, Flint KM, Goldwater DS, Dodson JA, **Afilalo J**, Maurer MS, Rich MW, Alexander KP, Hummel SL. Perspectives on Implementing a Multidomain Approach to Caring for Older Adults With Heart Failure. *J Am Geriatr Soc*. 2019 Dec;67(12):2593-2599. doi: 10.1111/jgs.16183. Epub 2019 Oct 18.

--Hoogendijk EO, **Afilalo J**, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. *Lancet*. 2019 Oct 12;394(10206):1365-1375. doi: 10.1016/S0140-6736(19)31786-6. Review.

--**Afilalo J**. Evaluating and Treating Frailty in Cardiac Rehabilitation. *Clin Geriatr Med*. 2019 Nov;35(4):445-457. doi: 10.1016/j.cger.2019.07.002. Epub 2019 Jul 2. Review.

--Chetrit M, **Afilalo J**. Authors' Reply. *J Am Soc Echocardiogr*. 2019 Sep;32(9):1250. doi: 10.1016/j.echo.2019.07.011.

--Blissett S, Chocron Y, Kovacina B, **Afilalo J**. Diagnostic and prognostic value of cardiac magnetic resonance in acute myocarditis: a systematic review and meta-analysis. *Int J Cardiovasc Imaging*. 2019 Dec;35(12):2221-2229. doi: 10.1007/s10554-019-01674-x. Epub 2019 Aug 6.

--Muscedere J, Kim PM, **Afilalo J**, Balion C, Baracos VE, Bowdish D, Cesari M, Erusalimsky JD, Fülöp T, Heckman G, Howlett SE, Khadaroo RG, Kirkland JL, Rodriguez Mañas L, Marzetti E, Paré G, Raina P, Rockwood K, Sinclair A, Skappak C, Verschoor C, Walter S. Proceedings of the Canadian Frailty Network Workshop: Identifying Biomarkers of Frailty to Support Frailty Risk Assessment, Diagnosis and Prognosis. Toronto, January 15, 2018. *J Frailty Aging*. 2019;8(3):106-116. doi: 10.14283/jfa.2019.12.

--Hosler QP, Maltagliati AJ, Shi SM, **Afilalo J**, Popma JJ, Khabbaz KR, Laham RJ, Guibone K, Kim DH. A Practical Two-Stage Frailty Assessment for Older Adults Undergoing Aortic Valve Replacement. *J Am Geriatr Soc*. 2019 Oct;67(10):2031-2037. doi: 10.1111/jgs.16036. Epub 2019 Jun 18. PubMed PMID: 31211413; PubMed Central PMCID: PMC6800747.

--**Beauchet O**, Fung S, Launay CP, Cooper-Brown LA, **Afilalo J**, Herbert P, Afilalo M, Chabot J. Screening for older inpatients at risk for long length of stay: which clinical tool to use? *BMC Geriatr*. 2019 Jun 6;19(1):156. doi: 10.1186/s12877-019-1165-4.

--Drudi LM, Ades M, Mancini R, Boudrias C, Obrand DI, Steinmetz OK, **Afilalo J**. Frailty assessment in older adults undergoing interventions for peripheral arterial disease. *J Vasc Surg*. 2019 Nov;70(5):1594-1602.e1. doi: 10.1016/j.jvs.2018.12.052. Epub 2019 May 18.

--Walston J, Bandeen-Roche K, Buta B, **Bergman H**, Gill TM, Morley JE, Fried LP, Robinson TN, **Afilalo J**, Newman AB, López-Otín C, De Cabo R, Theou O, Studenski S, Cohen HJ, Ferrucci L. Moving Frailty Toward Clinical Practice: NIA Intramural Frailty Science Symposium Summary. *J Am Geriatr Soc*. 2019 Aug;67(8):1559-1564. doi: 10.1111/jgs.15928. Epub 2019 May 2. PubMed PMID: 31045254; PubMed Central PMCID: PMC6830521.

--Sathananthan J, Lauck S, Piazza N, Martucci G, Kim DH, Popma JJ, Asgar AW, Perrault LP, Lefèvre T, Labinaz M, Lamy A, Peterson MD, Arora RC, Noiseux N, Généreux P, Webb JG, **Afilalo J**. Habitual Physical Activity in Older Adults Undergoing TAVR: Insights From the FRAILTY-AVR Study. *JACC Cardiovasc Interv*. 2019 Apr 22;12(8):781-789. doi: 10.1016/j.jcin.2019.02.049.

--Shi SM, Sung M, **Afilalo J**, Lipsitz LA, Kim CA, Popma JJ, Khabbaz KR, Laham RJ, Guibone K, Lee J, Marcantonio ER, Kim DH. Delirium Incidence and Functional Outcomes After Transcatheter and Surgical Aortic Valve Replacement. *J Am Geriatr Soc*. 2019 Jul;67(7):1393-1401. doi: 10.1111/jgs.15867. Epub 2019 Mar 18.

--Pighi M, Piazza N, Martucci G, Lachapelle K, Perrault LP, Asgar AW, Lauck S, Webb JG, Popma JJ, Kim DH, Lefèvre T, Labinaz M, Lamy A, Peterson MD, Arora RC, Noiseux N, Trnkus A, **Afilalo J**. Sex-Specific Determinants of Outcomes After Transcatheter Aortic Valve Replacement. *Circ Cardiovasc Qual Outcomes*. 2019 Mar;12(3):e005363. doi: 10.1161/CIRCOUTCOMES.118.005363.

--Chetrit M, Roujol S, Picard MH, Timmins L, Manning WJ, **Rudski LG**, Levine RA, **Afilalo J**. Optimal Technique for Measurement of Linear Left Ventricular Dimensions. *J Am Soc Echocardiogr*. 2019 Apr;32(4):476-483.e1. doi: 10.1016/j.echo.2018.12.001. Epub 2019 Feb 28.

--Mullie L, **Afilalo J**. CoreSlicer: a web toolkit for analytic morphomics. *BMC Med Imaging*. 2019 Feb 11;19(1):15. doi: 10.1186/s12880-019-0316-6.

--**Afilalo J**, Joshi A, Mancini R. If You Cannot Measure Frailty, You Cannot Improve It. *JACC Heart Fail*. 2019 Apr;7(4):303-305. doi: 10.1016/j.jchf.2018.12.015. Epub 2019 Feb 6.

--Kim DH, **Afilalo J**, Shi SM, Popma JJ, Khabbaz KR, Laham RJ, Grodstein F, Guibone K, Lux E, Lipsitz LA. Evaluation of Changes in Functional Status in the Year After Aortic Valve Replacement. *JAMA Intern Med*. 2019 Mar 1;179(3):383-391. doi: 10.1001/jamainternmed.2018.6738.

--Drudi LM, Ades M, Landry T, Gill HL, Grenon SM, Steinmetz OK, **Afilalo J**. Scoping review of frailty in vascular surgery. *J Vasc Surg*. 2019 Jun;69(6):1989-1998.e2. doi: 10.1016/j.jvs.2018.10.053. Epub 2018 Dec 24. Review.

--Tremblay-Gravel M, Marquis-Gravel G, Avram R, Desplantie O, Ducharme A, Bibas L, Pacheco C, Couture E, Simard F, Poulin A, Malhamé I, Tran D, Rey E, Tournoux F, Harvey L, Sénéchal M, Bélisle P, Descarries L, Farand P, Pranno N, Diaz A, **Afilalo J**, Ly HQ, Fortier A, Jolicoeur EM; BRO-HF investigators. The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO-HF retrospective cohort study. *ESC Heart Fail*. 2019 Feb;6(1):27-36. doi: 10.1002/ehf2.12376. Epub 2018 Nov 22.

--Yanagawa B, Graham MM, **Afilalo J**, Hassan A, Arora RC. Frailty as a risk predictor in cardiac surgery: Beyond the eyeball test. *J Thorac Cardiovasc Surg*. 2019 May; 157(5):1905-1909. doi: 10.1016/j.jtcvs.2018.08.054. Epub 2018 Sep 5.

--Shi S, **Afilalo J**, Lipsitz LA, Popma JJ, Khabbaz KR, Laham RJ, Guibone K, Grodstein F, Lux E, Kim DH. Frailty Phenotype and Deficit Accumulation Frailty Index in Predicting Recovery After Transcatheter and Surgical Aortic Valve Replacement. *J Gerontol A Biol Sci Med Sci*. 2019 Jul 12;74(8):1249-1256. doi: 10.1093

Assouline, Sarit

--Landsburg DJ, Ayers EC, Bond DA, Maddocks KJ, Karmali R, Behdad A, Curry M, Wagner-Johnston ND, Modi D, Ramchandren R, **Assouline SE**, Faramand R, Chavez JC, Torka P, Mier Hicks A, Medeiros LJ, Li S. Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. *Br J Haematol*. 2019 Dec 5. doi: 10.1111/bjh.16319. [Epub ahead of print]

--Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, **Assouline S**, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). *Lancet Haematol*. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29.

--Flinn IW, Miller CB, Ardeschna KM, Tetreault S, **Assouline SE**, Mayer J, Merli M, Lunin SD, Pettitt AR, Nagy Z, Tournilhac O, Abou-Nassar KE, Crump M, Jacobsen ED, de Vos S, Kelly VM, Shi W, Steelman L, Le N, Weaver DT, Lustgarten S, Wagner-Johnston ND, Zinzani PL. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. *J Clin Oncol*. 2019 Apr 10;37(11):912-922. doi: 10.1200/JCO.18.00915. Epub 2019 Feb 11. Erratum in: *J Clin Oncol*. 2019 Jun 1;37(16):1448.

--Awan FT, Thirman MJ, Patel-Donnelly D, **Assouline S**, Rao AV, Ye W, Hill B, Sharman JP. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. *Leuk Lymphoma*. 2019 Aug;60(8):1972-1977. doi: 10.1080/10428194.2018.1562180. Epub 2019 Jan 11.

--Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Busque L, **Assouline SE**; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP). Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study. *Haematologica*. 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10. No abstract available.

--Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, **Assouline S**, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. *J Clin Oncol*. 2019 Feb 20;37(6):481-489. doi: 10.1200/JCO.18.00766. Epub 2019 Jan 8.

--Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, **Assouline SE**; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP). Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia. *Cancer*. 2019 Feb 15;125(4):618-625. doi: 10.1002/cncr.31835. Epub 2018 Nov 13.

--Bixby D, Noppeney R, Lin TL, Cortes J, Krauter J, Yee K, Medeiros BC, Krämer A, **Assouline S**, Fiedler W, Dimier N, Simmons BP, Riehl T, Colburn D. Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. *Br J Haematol*. 2019 May;185(3):595-598. doi: 10.1111/bjh.15571. Epub 2018 Sep 11. No abstract available.

--Andorsky DJ, Kolibaba KS, **Assouline S**, Forero-Torres A, Jones V, Klein LM, Patel-Donnelly D, Smith M, Ye W, Shi W, Yassenchak CA, Sharman JP. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. *Br J Haematol*. 2019 Jan;184(2):215-222. doi: 10.1111/bjh.15552. Epub 2018 Sep 5.

Baron, Murray

--Ellingwood L, Schieir O, Valois MF, Bartlett SJ, Bessette L, Boire G, Hazlewood G, Hitchon C, Keystone EC, Tin D, Thorne C, Bykerk VP, Pope JE, **Baron M**, Bessette L, Boire G, Bykerk V, Colmegna I, Fallavollita S, Haaland D, Haraoui P, Hazlewood G, Hitchon C, Jamal S, Joshi R, Keystone E, Nair B, Panopoulos P, Pope J, Rubin L, Thorne C, Villeneuve E, Zummer M. Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results from an Incident Cohort. *ACR open rheumatology* 2019;1:614-9.

--Pokharel G, Deardon R, Barnabe C, Bykerk V, Bartlett SJ, Bessette L, Boire G, Hitchon CA, Keystone E, Pope J, Schieir O, Tin D, Thorne C, Hazlewood GS, **Baron M**, Bessette L, Boire G, Bykerk V, Colmegna I, Fallavollita S, Haaland D, Haraoui P, Hazlewood G, Hitchon C, Jamal S, Joshi R, Keystone E, Nair B, Panopoulos P, Penney C, Pope J, Rubin L, Thorne C, Villeneuve E, Zummer M. Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. *ACR open rheumatology* 2019;1:471-9.

--Nevskaya T, Zheng B, Baxter CA, Ramey DR, Pope JE, **Baron M**. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. *Rheumatology (Oxford, England)* 2019.

--He C, Levis B, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Krishnan A, Wu Y, Sun Y, Imran M, Boruff J, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, **Baron M**, Beraldi A, Bombardier CH, Butterworth P, Carter G, Chagas MHN, Chan JCN, Cholera R, Clover K, Conwell Y, de Man-van Ginkel JM, Fann JR, Fischer FH, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Harrison PA, Harter M, Hegerl U, Hides L, Hobfoll SE, **Hudson M**, Hyphantis TN, Inagaki M, Ismail K, Jette N, Khamseh ME, Kiely KM, Kwan Y, Lamers F, Liu SI, Lotrakul M, Loureiro SR, Lowe B, Marsh L, McGuire A, Mohd-Sidik S, Munhoz TN, Muramatsu K, Osorio FL, Patel V, Pence BW, Persoons P, Picardi A, Reuter K, Rooney AG, da Silva Dos Santos IS, Shaaban J, Sidebottom A, Simning A, Stafford L, Sung S, Tan PLL, Turner A, van Weert H, White J, Whooley MA, Winkley K, Yamada M, Thombs BD, Benedetti A. The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. *Psychotherapy and psychosomatics* 2019;1-13.

--Hoa S, Bernatsky S, Steele RJ, **Baron M**, **Hudson M**. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. *Rheumatology (Oxford, England)* 2019.

--Ross L, Stevens W, Wilson M, Strickland G, Walker J, Sahhar J, Ngian GS, Roddy J, Major G, Proudman S, **Baron M**, Nikpour M. Can patient-reported symptoms be used to measure disease activity in systemic sclerosis? *Arthritis care & research* 2019.

--Zheng B, Nevskaya T, Baxter CA, Ramey DR, Pope JE, **Baron M**. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. *Rheumatology (Oxford, England)* 2019.

--Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, **Baron M**, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudau S, Riggs R, Sauve M, Wigley F, **Hudson M**, Bartlett SJ. Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. *Rheumatology (Oxford, England)* 2019.

--Wu Y, Levis B, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Boruff J, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, **Baron M**, Bombardier CH, Butterworth P, Carter G, Chagas MH, Chan JCN, Cholera R, Conwell Y, de Man-van Ginkel JM, Fann JR, Fischer FH, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Harrison PA, Harter M, Hegerl U, Hides L, Hobfoll SE, **Hudson M**, Hyphantis T, Inagaki MD, Jette N, Khamseh ME, Kiely KM, Kwan Y, Lamers F, Liu SI, Lotrakul M, Loureiro SR, Lowe B, McGuire A, Mohd-Sidik S, Munhoz TN, Muramatsu K, Osorio FL, Patel V, Pence BW, Persoons P, Picardi A, Reuter K, Rooney AG, Santos IS, Shaaban J, Sidebottom A, Simning A, Stafford MD, Sung S, Tan PLL, Turner A, van Weert HC, White J, Whooley MA, Winkley K, Yamada M, Benedetti A, Thombs BD. Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. *Psychological medicine* 2019;1-13.

--**Baron M**, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton C, Domsic RT, Ferdowski N, Foeldvari I, Frech T, Gordon JK, **Hudson M**, Johnson SR, Khanna D, McMahan Z, Merkel PA, Narain S, Nikpour M, Pauling JD, Ross L, Valenzuela Vergara AM, Vacca A. An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. *Journal of scleroderma and related disorders* 2019;4:17-27.

--Ferdowski N, Stevens W, **Baron M**, Nikpour M. Damage indices in rheumatic diseases: A systematic review of the literature. *Seminars in arthritis and rheumatism* 2019;49:27-34.

--Butler EA, **Baron M**, Fogo AB, Frech T, Ghossein C, Hachulla E, Hoa S, Johnson SR, Khanna D, Mouthon L, Nikpour M, Proudman S, Steen V, Stern E, Varga J, Denton C, **Hudson M**. Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. *Arthritis & rheumatology (Hoboken, NJ)* 2019;71:964-71.

--Ross L, Prior D, Proudman S, Vacca A, **Baron M**, Nikpour M. Defining primary systemic sclerosis heart

involvement: A scoping literature review. *Seminars in arthritis and rheumatism* 2019;48:874-87.

--Harel D, **Baron M**. Methods for shortening patient-reported outcome measures. *Statistical methods in medical research* 2019;28:2992-3011.

Batist, Gerald

--Aguilar-Mahecha A, Joseph S, Cavallone L, Buchanan M1, Krzemien U, **Batist G**, Basik M. Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report. *Front Oncol.* 2019 Aug;9:698.

--Blank-Landeshammer B, Richard VR, Mitsa G, Marques M, LeBlanc A, Kollipara L, Feldmann I, Couetoux du Tertre M, Gambaro K, McNamara S, Spatz A, Zahedi RP, Sickmann A, **Batist G**, Borchers CH. Proteogenomics of colorectal cancer liver metastases: complementing precision oncology with phenotypic data. *Cancers (Basel)*.2019 Dec 1;11(12). pii: E1907.

--Higenell V, Fajzel R, **Batist G**, Cheema PK, McArthur HL, Melosky B, Morris D, Petrella TM, Sangha R, Savard MF, Sridhar SS, Stagg J, Stewart DJ, Verma S. A network approach to developing immuno-oncology combinations in Canada. *Curr Oncol.* 2019 Apr;26(2):73-79.

--Sinha S, Brown H, Tabak J, Fang Z, Tertre MCD, McNamara S, Gambaro K, **Batist G**, Buell JF. Multiplexed real-time polymerase chain reaction cell-free DNA assay as a potential method to monitor stage IV colorectal cancer. *Surgery.* 2019 Oct;166(4):534-539.

--Sobsey CA, Ibrahim S, Richard VR, Gaspar V, Mitsa G, Lacasse V, Zahedi RP, **Batist G**, Borchers CH. Targeted and Untargeted Proteomics Approaches in Biomarker Development. *Proteomics.* 2019 Nov; e1900029. doi: 10.1002/pmic.201900029.

Olivier Beauchet

--**Beauchet O**, Launay CP, Galery K, Vilcoq C, Dontot-Payen F, Rousseau B, Benoit V, Allali G. Effects of Vitamin D and Calcium Fortified Yogurts on Gait, Cognitive Performances, and Serum 25-Hydroxyvitamin D Concentrations in Older Community-Dwelling Females: Results from the GAit, MEmory, Dietary and Vitamin D (GAME-D2) Randomized Controlled Trial. *Nutrients.* 2019 [Epub ahead of print]

--Foucault G, Duval GT, Simon R, **Beauchet O**, Dinomais M, Annweiler C. Serum Vitamin D and Cingulate Cortex Thickness in Older Adults: Quantitative MRI of the Brain. *Curr Alzheimer Res.* 2019 [Epub ahead of print]

--Cossette B, Bruneau MA, Couturier Y, Gilbert S, Boyer D, Ricard J, McDonald T, Labarre K, Déry V, Arcand M, Rodrigue C, Rhéaume AA, Moreault S, Allard C, Pépin MÉ, **Beauchet O**; OPUS-AP investigators. Optimizing Practices, Use, Care and Services-Antipsychotics (OPUS-AP) in Long-term Care Centers in Québec, Canada: A Strategy for Best Practices. *J Am Med Dir Assoc.* 2019 [Epub ahead of print]

--Allali G, Montembeault M, Griffa A, **Beauchet O**. Default mode network and the timed up and go in MCI: A structural covariance analysis. *ExpGerontol.* 2019 [Epub ahead of print]

--**Beauchet O**, Sekhon H, Launay CP, Rolland Y, Schott AM, Allali G. Motoric cognitive risk syndrome and incident dementia: results from a population-based prospective and observational cohort study. *Eur J Neurol.* 2019 [Epub ahead of print]

--Sekhon H, Allali G, **Beauchet O**. The association of anxio-depressive disorders and depression with motoric cognitive risk syndrome: results from the baseline assessment of the Canadian longitudinal study on aging. *Geroscience.* 2019;41(4):409-418.

--Sekhon H, Allali G, **Beauchet O**. Motoric cognitive risk syndrome and cardiovascular diseases and risk factors

in the Canadian population: Results from the baseline assessment of the Canadian longitudinal study on aging. *Arch GerontolGeriatr.* 2019 [Epub ahead of print]

--Crockett RA, Hsu CL, Best JR, **Beauchet O**, Liu-Ambrose T. Head over heels but I forget why: Disruptive functional connectivity in older adult fallers with mild cognitive impairment. *Behav Brain Res.* 2019 [Epub ahead of print]

--**Beauchet O**, Sekhon H, Schott AM, Rolland Y, Muir-Hunter S, Markle-Reid M, Gagne H, Allali G. Motoric Cognitive Risk Syndrome and Risk for Falls, Their Recurrence, and Postfall Fractures: Results From a Prospective Observational Population-Based Cohort Study. *J Am Med Dir Assoc.* 2019;20(10):1268-1273.

--**Beauchet O**, Fung S, Launay CP, Cooper-Brown LA, **Afilalo J**, Herbert P, Afilalo M, Chabot J. Screening for older inpatients at risk for long length of stay: which clinical tool to use? *BMC Geriatr.* 2019;19(1):156

--Allali G, Montembeault M, Saj A, Wong CH, Cooper-Brown LA, Bherer L, **Beauchet O**. Structural Brain Volume Covariance Associated with Gait Speed in Patients with Amnesic and Non-Amnesic Mild Cognitive Impairment: A Double Dissociation. *J Alzheimers Dis.* 2019;71(s1):S29-S39.

--**Beauchet O**, Montembeault M, Barden JM, Szturm T, Bherer L, Liu-Ambrose T, Chester VL, Li K, Helbostad JL, Allali G; Canadian Gait Consortium. Brain gray matter volume associations with gait speed and related structural covariance networks in cognitively healthy individuals and in patients with mild cognitive impairment: A cross-sectional study. *ExpGerontol.* 2019;122:116-122.

--Sekhon H, Allali G, Launay CP, Barden J, Szturm T, Liu-Ambrose T, Chester VL, Wong CH, **Beauchet O**; Canadian Gait Consortium. Motoric cognitive risk syndrome, incident cognitive impairment and morphological brain abnormalities: Systematic review and meta-analysis. *Maturitas.* 2019;123:45-54.

--De Cock AM, Fransen E, Perkisas S, Verhoeven V, **Beauchet O**, Vandewoude M, Remmen R. Comprehensive Quantitative Spatiotemporal Gait Analysis Identifies Gait Characteristics for Early Dementia Subtyping in Community Dwelling Older Adults. *Front Neurol.* 2019;10:313.

--Chabot J, **Beauchet O**, Fung S, Peretz I. Decreased risk of falls in patients attending music sessions on an acute geriatric ward: results from a retrospective cohort study. *BMC Complement Altern Med.* 2019;19(1):76.

--**Beauchet O**, Launay CP, Chabot J, Dejager S, Bineau S, Galery K, Berrut G. Prediction of unplanned hospital admissions in older community dwellers using the 6-item Brief Geriatric Assessment: Results from REPERAGE, an observational prospective population-based cohort study. *Maturitas.* 2019;122:1-7.

--Sekhon H, Launay CP, Chabot J, Allali G, **Beauchet O**. Motoric Cognitive Risk Syndrome: Could It Be Defined Through Increased Five-Times-Sit-to-Stand Test Time, Rather Than Slow Walking Speed? *Front Aging Neurosci.* 2019;10:434.

--**Beauchet O**, Sekhon H, Launay CP, Chabot J, Rolland Y, Schott AM, Allali G. Motoric cognitive risk syndrome and mortality: results from the EPIDOS cohort. *Eur J Neurol.* 2019;26(5):794-e56.

--**Beauchet O**, Launay CP, Sekhon H, Montembeault M, Allali G. Association of hippocampal volume with gait variability in pre-dementia and dementia stages of Alzheimer disease: Results from a cross-sectional study. *ExpGerontol.* 2019;115:55-61.

--Blumen HM, Allali G, **Beauchet O**, Lipton RB, Verghese J. A Gray Matter Volume Covariance Network Associated with the Motoric Cognitive Risk Syndrome: A Multicohort MRI Study. *J Gerontol A BiolSci Med Sci.* 2019;74(6):884-889.

--Allali G, Montembeault M, Brambati SM, Bherer L, Blumen HM, Launay CP, Liu-Ambrose T, Helbostad JL, Verghese J, **Beauchet O**. Brain Structure Covariance Associated With Gait Control in Aging. *J Gerontol A BiolSci Med Sci.* 2019;74(5):705-713.

--Blumen HM, Brown LL, Habeck C, Allali G, Ayers E, **Beauchet O**, Callisaya M, Lipton RB, Mathuranath PS, Phan TG, Pradeep Kumar VG, Srikanth V, Verghese J. Gray matter volume covariance patterns associated with gait speed in older adults: a multi-cohort MRI study. *Brain Imaging Behav.* 2019;13(2):446-460.

--Hsu CL, Best JR, Voss MW, Handy TC, **Beauchet O**, Lim C, Liu-Ambrose T. Functional Neural Correlates of Slower Gait Among Older Adults With Mild Cognitive Impairment. *J Gerontol A BiolSci Med Sci.* 2019;74(4):513-518.

Bergman, Howard

--Boychuck, Z. , Andersen, J. , Bussi eres, A. , Fehlings, D. , Kirton, A. , Li, P. , Oskoui, M. , Rodriguez, C. , Shevell, M. , Snider, L. , Majnemer, A. , & the **PROMPT group**. (2019). Use of consensus methods to determine the early clinical signs of cerebral palsy. *Paediatrics& Child Health.* 2019 May. DOI: 10.1093/pch/pxz061

--Karunanathan S, Moodie EEM, **Bergman H**, Payette H, Wolfson D, Diehr PH, Wolfson C. The association between physical function and proximity to death in older adults: a multilevel analysis of 4,150 decedents from the Cardiovascular Health Study. *Ann Epidemiol.* 2019 Jul;35:59-65. e5. doi: 10.1016/j.annepidem.2019.04.005. Epub 2019 Apr 18.

--Vedel I, Sourial N, Arsenaault-Lapierre G, Godard-Sebillotte C, **Bergman H**. Impact of the Quebec Alzheimer Plan on the detection and management of Alzheimer disease and other neurocognitive disorders in primary health care: a retrospective study. *CMAJ Open* 2019;7(2):E391-8. doi:10.9778/cmajo.20190053.

--Guillette M, Couturier Y, Moreau O, Gagnon D, **Bergman H**, Vedel I. Gouvernance et accompagnement du changement : le cas de la phase exp erimentale du Plan Alzheimer du Qu ebec. *Innovations*2019/3 (N o 60), pages 145   168

--Dent E, Finbarr N, **Bergman H**, Woo J, Romero-Ortuno R, Walston J. The Management of Frailty: Opportunities, Challenges, and Future Directions. *The Lancet.* 2019; Vol. 394, Issue 10206:1376-86. [https://doi.org/10.1016/S0140-6736\(19\)31785-4](https://doi.org/10.1016/S0140-6736(19)31785-4)

--Boychuck Z, Andersen J, Bussi eres A, Fehlings D, Kirton A, Li P, Oskoui M, Rodriguez C, Shevell M, Snider L, Majnemer A, & the **PROMPT group**. (2020). International expert recommendations of clinical features to prompt referral for diagnostic assessment of cerebral palsy. *Developmental Medicine & Child Neurology.* 2019 Jan;62(1), 89-96. DOI: 10.1111/dmcn.14252

Blank, Volker

--Saliba J, Coutaud B, Solovieva V, Lu F, & Blank V. Regulation of CXCL1 chemokine and CSF3 cytokine levels in myometrial cells by the MAFF transcription factor. *Journal of Cellular and Molecular Medicine* 2019, 23: 2517-25.

--Bury M, Le Calv e B, Dal Maso T, Saliba J, Lessard F, Ferbeyre G, Michiels C & Blank V. NFE2L3 controls colon cancer cell growth through regulation of DUX4, a CDK1 inhibitor. *Cell Reports* 2019, 29: 1469-181. e9.

Blum, Daniel

--**Blum D**, Beaubien-Souigny W, Silver SA, Wald R. Thinking Volume First: Developing a Multifaceted Systematic Approach to Volume Management in Hemodialysis. *Canadian Journal of Kidney Health and Disease.* Volume 6, pages 1-11, 2019.

--Beaubien-Souigny W, Kontar L, **Blum D**, Bouchard J, Denault AY, Wald R. Meta-Analysis of Randomized Controlled Trials Using Tool-Assisted Target Weight Adjustments in Chronic Dialysis Patients. *Kidney International Reports.* Volume 4, pages 1426–1434, 2019.

Blostein, Mark

--Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, Vanassche T, Verhamme P, Shivakumar S, Gross PL, Lee AYY, Yeo E, Solymoss S, Kassis J, Le Templier G, Kowalski S, **Blostein M**, Shah V, MacKay E, Wu C, Clark NP, Bates SM, Spencer FA, Arnaoutoglou E, Coppens M, Arnold DM, Caprini JA, Li N, Moffat KA, Syed S, Schulman S. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. *JAMA Intern Med.* 2019 Aug 5. doi: 10.1001/jamainternmed.2019.2431. [Epub ahead of print].

--Arnold DM, Jamula E, Heddle NM, Cook RJ, Hsia C, Sholzberg M, Lin Y, Kassis J, **Blostein M**, Larratt L, Amini S, Schipperus M, Carruthers J, Lane SJ, Li N, Kelton JG. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopenia (The Bridging ITP Trial): Methods and Rationale. *Thromb Haemost.* 2019 Mar;119(3):500-507. doi: 10.1055/s-0038-1677531. Epub 2019 Jan 27.

--Cocciolillo S, Sebastiani G, **Blostein M** and Pantopoulos K. (2019) Liver hormones, Hormonal Signaling in Biology and Medicine (ed Litwack, G.), Academic Press/Elsevier, 425-444.

--Bertin FR, Rys RN, Mathieu C, Laurance S, Lemarié CA, **Blostein MD**. Natural killer cells induce neutrophil extracellular trap formation in venous thrombosis. *J Thromb Haemost.* 2019 Feb;17(2):403-414.

Brenner, Bluma

--Villandré L, Labbe A, **Brenner B**, Roger M, Stephens DA. Assessing the role of transmission chains in the HIV-1 epidemic among men who have sex with men in Quebec, Canada. *PLOS One* 2019 Mar 6; 14(3), e0213366: 1-16.

--Chaillon A, Delauger C, **Brenner B**, Armero A, Capitant C, Nere ML, Pialoux G, Cua E, Tremblay C, Smith DM, Goujard C, Meyer L, Molina JM, and Chaix ML. In-depth sampling of high-risk populations to characterize HIV transmission epidemics among young MSM using PrEP in France and Quebec. *Open Forum Infectious Diseases* 2019, Feb 15;6(3):1-7.

Cummings, Beth Ann

--Dory V, **Cummings BA**, Mondou M, Young M (2019). Nudging clinical supervisor to provide better in-training evaluation reports. *Perspectives in Medical Education*. Published online: December 17, 2019. DOI 10.1007/s40037-019-00554-3.

--Pal NE, Young M, Danoff D, Plotnick LH, **Cummings BA**, Gomez-Garibello C, Dory V (2019). Teachers' Mindsets in Medical Education: A Pilot Survey of Clinical Supervisors. *Medical Teacher*. Published online: October 22, 2019. doi: 10.1080/0142159X.2019.1679359.

--*Bilodeau PA, *Liu XM, **Cummings BA** (2019). Partnered educational governance: rethinking student agency in undergraduate medical education. *Academic Medicine*. *Academic Medicine*. 94:1443–1447. First published online April 30, 2019. doi: 10.1097/ACM.0000000000002777.

Douros, A.

--**Douros A***, Toelle M*, Ebert N, Gaedeke J, Huscher D, Kreutz R, Kuhlmann M, Martus P, Mielke N, Schneider A, Schuchardt M, van der Giet M, Schaeffner E. Control of blood pressure and risk of mortality in a cohort of older adults: The Berlin Initiative Study *Eur Heart J.* 2019 Jul; 40(25): 2021-2028.

--**Douros A**, Dell'Aniello S, Dehghan G, Boivin JF, Renoux C. Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: a cohort study. *Neurology.* 2019 Sep; 93(10): e1010-e1020.

--Khosrow-Khavar F, Kurteva S, **Douros A**. Re: Metformin use and gastric cancer risk in diabetic patients after

Helicobacter pylori eradication. J Natl Cancer Inst. 2019 Oct 1;111(10):1107-1108.

--Kreutz R, Algharably EAH, **Douros A**. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. J Hypertens. 2019 Oct; 37(10): 1950-1958.

--Sommet A, Benevent J, Rousseau V, Chebane L, **Douros A**, Montastruc JL, Montastruc F. What fluoroquinolones have the highest risk of aortic aneurysms? A case/non-case study in VigiBase® J Gen Intern Med. 2019 Apr; 34(4): 502-503.

Eintracht, Shaun

--Pang SA, **Eintracht S**, Schwartz JM, Lobo B, **MacNamara E**. Hypersensitivity reactions to high osmolality Total Parenteral Nutrition: a case report. Allergy Asthma Clin Immunol. 2019 Aug 30;15:51.

--Brukner I, **Eintracht S**, Forgetta V, Papadakis AI, Spatz A, Oughton M. Laboratory-developed test for detection of acute Clostridium difficile infections with the capacity for quantitative sample normalization. Diagn Microbiol Infect Dis. 2019 Oct;95(2):113-118

Eisenberg, Mark

--Al Kharji S, Connell T, Bernier M, **Eisenberg MJ**. Ionizing Radiation in Interventional Cardiology and Electrophysiology. 35(4):535-538. Can J Cardiol 2019.

--Singh S, **Filion KB**, Abenhaim HA, **Eisenberg MJ**. Prevalence and Outcomes of Prenatal Recreational Cannabis Use in High-Income Countries: A Scoping Review. 127:8-16. BJOG 2020. Epub 2019 Oct 24.

--Windle SB, Wade K, **Filion KB**, Gore G, Kimmelman J, Thombs BD, **Eisenberg MJ**. Potential harms from legalization of recreational cannabis use in Canada. Can J Public Health, 110(2):222-226. 2019.

--**Eisenberg MJ**. Case Studies in Interventional Cardiology. McGraw-Hill Education 2019.

Ernst, Peter

--Daneman N, Chateau D, Dahl M, Zhang J, Fisher A, Sketris IS, Quail J, Marra F, **Ernst P**, Bugden S, Canadian Network for Observational Drug Effect Studies I. Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study. [published online ahead of print, 2019 Oct 23]. Clin Microbiol Infect. 2019;S1198-743X(19)30552-X.

--**Ernst P**, Dahl M, Chateau D, Daneman N, Quail J, Sketris IS, Fisher A, Zhang J, Bugden S. Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study. Int J Chron Obstruct Pulmon Dis. 2019;14:2939-2946.

--**Suissa S**, Dell'Aniello S, **Ernst P**. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest 2019 Jun;155(6):1158-1165.

--**Suissa S**, Dell'Aniello S, **Ernst P**. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice. Chest. 2019 Nov 22. pii: S0012-3692(19)34225-4.

--**Suissa S**, Dell'Aniello S, Gonzalez AV, **Ernst P**. Inhaled corticosteroid use and the incidence of lung cancer in COPD. EurRespir J. 2019 Nov 19. pii: 1901720.

--**Suissa S**, Ernst P. Beta-blockers in COPD: A methodological review of the observational studies. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2019 Jan 13, 15:5, 520-525.

--**Suissa S**, **Hudson M**, Dell'Aniello S, Shen S, Simon TA, **Ernst P**. Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study. Semin Arthritis Rheum.

2019 Dec;43(3):366-372.

Farge, Dominique

--Zephir H, Puyade M, Gueguen A, Michel L, Terriou L, Dive D, Laureys G, Mathey G, Labauge P, Marjanovic Z, Pugnet G, Badoglio M, Lansiaux P, Yakoub-Agha I, Béguin Y, **Farge D**. Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis. *Bull Cancer*. 2019 Jan;106(1S):S92-S101. doi: 10.1016/j.bulcan.2018.11.002.

--Frere C, **Farge D**. The best direct-acting oral anticoagulant for treatment of venous thromboembolism? *Lancet Haematol*. 2019 Jan;6(1):e4-e5. doi: 10.1016/S2352-3026(18)30211-4.

--Frere C, Benzidia I, Marjanovic Z, **Farge D**. Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. *Cancers (Basel)*. 2019 Jan 10;11(1). pii: E71.

--Guillaume-Jugnot P, Badoglio M, Labopin M, Terriou L, Yakoub-Agha I, Martin T, Lioure B, Marjanovic Z, Blaise D, Nguyen S, Pugnet G, Huynh A, Deligny C, Seinturier C, Garban F, Swiader L, Bay JO, Braun T, de Latour RP, Rubio MT, **Farge D**. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). *Clin Rheumatol*. 2019 Jan 21. doi: 10.1007/

--Jessop H, **Farge D**, Saccardi R, Alexander T, Rovira M, Sharrack B, Greco R, Wulffraat N, Moore J, Kazmi M, Badoglio M, Adams G, Verhoeven B, Murray J, Snowden JA. General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). *Bone Marrow Transplant*. 2019 Jan 31. doi: 10.1038/s41409-019-0430-

--Debourdeau P, Arvers P, Hij A, Bennani H, Desauw C, Falvo N, Ghiringhelli F, Hamadé A, Vedrine L, **Farge D**. Factors influencing patient's perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study. *Support Care Cancer*. 2019 May 1. doi: 10.1007/s00520-019-04815-z. [Epub ahead of print]

--Wen L, Labopin M, Badoglio M, Wang D, Sun L, **Farge-Bancel D**. Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells. 2019 May 2;2019:7061408. doi: 10.1155/2019/7061408. eCollection 2019.

--E Fuentes H, J Tafur A, A Caprini J, Alatri A, Trujillo-Santos J, **Farge-Bancel D**, Rosa V, Font L, Vilaseca A, Monreal M, for the RIETE Investigators**. Prediction of early mortality in Patients with Cancer-Associated Thrombosis (CAT) in the RIETE Database. *Int Angiol*. 2019 Jun;38(3):173-184. doi: 10.23736/S0392-9590.19.04110-5.

--**Farge D**, Frere C. Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. 2019 Jun 27;8. pii: F1000 Faculty Rev-974. doi: 10.12688/f1000research.18673.1. eCollection 2019

--Greco R, Labopin M, Badoglio M, Veys P, Furtado Silva JM, Abinun M, Gualandi F, Bornhauser M, Ciceri F, Saccardi R, Lankester A, Alexander T, Gennery AR, Bader P, **Farge D**, Snowden JA. Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. *Front Immunol*. 2019 Jul 4;10:1570. doi: 10.3389/fimmu.2019.01570. eCollection 2019.

--Vadasz Z, Balbir Gurman A, Meroni P, **Farge D**, Levi Y, Ingegnoli F, Braun-Moscovici Y, Rosner I, Slobodin G, Rozenbaum M, Jiries N, Kaly L, Boulman N, Zilber K, Ginsberg S, Awisat A, Goldberg Y, Lurie M, Ghigna MR, Guignabert C, Humbert M, Rimar D. Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study. *Rheumatology (Oxford)*. 2019 Sep 1;58(9):1547-1555. doi:

10.1093/rheumatology/kez035.

--**Farge D**, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brillhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol*. 2019 Sep 3. pii: S1470-2045(19)30336-5. doi: 10.1016/S1470-2045(19)30336-5.

--Miller P., Snowden J., Peffault de Latour R., Iacobelli S., Eikema D-J., Knol C., Marsh J., Rice C., Koh M., Fagioli F., Chaganti S., Finke J., Duarte R., Bader P., **Farge D**, Passweg J., Madrigal A., and Dufour C. Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: A joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant*. 2019 Sep 25. doi: 10.1038/s41409-019-0680-4.

--**Farge D**, Le Maignan C, Doucet L, Frere C. Women, thrombosis, and cancer. *Thromb Res*. 2019 Sep;181 Suppl 1:S47-S53. doi: 10.1016/S0049-3848(19)30367-6. Review.

--Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, **Farge D**, Greco R, Jessop H, Kazmi M, Kirgizov K, Labopin M, Mancardi G, Martin R, Moore J, Muraro PA, Rovira M, Sormani MP, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE). Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). *Bone Marrow Transplant*. 2019 Sep 26. doi: 10.1038/s41409-019-0684-0

--Tappenden P, Wang Y, Sharrack B, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, **Farge D**, Snowden JA. Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). *Bone Marrow Transplant*. 2019 Nov 19. doi: 10.1038/s41409-019-0747-2.

--Puyade M, Labeyrie C, Badoglio M, Cintas P, Guenounou S, Lansiaux P, Marjanovic Z, Nicolas G, Pomies A, Terriou L, Torregrosa Diaz JM, Baron C, Castilla Llorente C, Yakoub-Agha I, **Farge D**. [Indication of autologous stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. *Bull Cancer*. 2019 Dec 7. pii: S0007-4551(19)30403-5. doi: 10.1016/j.

--Douketis JD, Frere C, **Farge D**; International Thrombosis and Cancer Initiative members. 2019 international clinical practice guidelines for the treatment of venous thromboembolism - Authors' reply. *Lancet Oncol*. 2019 Dec;20(12):e656. doi: 10.1016/S1470-2045(19)30750-8.

--Alexander T, Samuelson C, Daikeler T, Henes J, Akil M, Skagerlind L, Ehninger G, Jantunen E, Badoglio M, **Farge D**, Snowden JA; EBMT Autoimmune Diseases Working Party. Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. *Bone Marrow Transplant*. 2019 Dec 17. doi: 10.1038/s41409-019-0763-2.

--Frere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, **Farge D**; BACAP Consortium. Incidence of Venous Thromboembolism in Patients with Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. *Gastroenterology*. 2019 Dec 13. pii: S0016-5085(19) 41921-5.

2019

--Butler EA, Baron M, Fogo AB, Frech T, Ghossein C, Hachulla E, Hoa S, Johnson SR, Khanna D, Mouthon L,

Nikpour M, Proudman S, Steen V, Stern E, Varga J, Denton C, Hudson M, Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group. Collaborators (57) **Farge D**. Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. *Arthritis Rheumatol*. 2019 Jan 7. doi: 10.1002/art.40809.

--Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Collaborators (218) **Farge D**. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. *N Engl J Med*. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.

--Mastroiacovo D, Dentali F, di Micco P, Maestre A, Jiménez D, Soler S, Sahuquillo JC, Verhamme P, Fidalgo Á, López-Sáez JB, Skride A, Monreal M; RIETE Investigators; Coordinator of the RIETE Registry: Manuel Monreal (Spain). RIETE Steering Committee Members; Members of the RIETE Group are as follows. Collaborators (174) **Farge D**. Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. *Eur Respir J*. 2019 Feb 21;53(2). pii: 1801677. doi: 10.1183/13993003.01677-2018. Print 2019 Feb.

--Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. Collaborators (230) **Farge D**. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. *Ann Rheum Dis*. 2019 Apr 9. pii: annrheumdis-2018-214816. doi: 10.1136/annrheumdis-2018-214816.

--Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, Cozzi F, Distler O, Matucci-Cerinic M, Denton C, Launay D, Hachulla E; EUSTAR collaborators. Collaborators (185) **Farge D**. Phenotypes determined by cluster analysis and their survival in the prospective EUSTAR cohort of patients with systemic sclerosis. *Arthritis Rheumatol*. 2019 Apr 10. doi: 10.1002/art.40906

--Avnery O, Martin M, Bura-Riviere A, Barillari G, Mazzolai L, Mahé I, Marchena PJ, Verhamme P, Monreal M, Ellis MH; RIETE Investigators. Collaborators (153) **Farge D**. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. *J Intern Med*. 2019 Aug 8. doi: 10.1111/joim.12969. [Epub ahead of print]PAYANT

--Riera-Mestre A, Mora-Luján JM, Trujillo-Santos J, Del Toro J, Nieto JA, Pedrajas JM, López-Reyes R, Soler S, Ballaz A, Cerdà P, Monreal M11; RIETE Investigators. Collaborators (193) **Farge D**. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry. *Orphanet J Rare Dis*. 2019 Aug 9;14(1):196. doi: 10.1186/s13023-019-1172-8.

--Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, Cozzi F, Distler O, Matucci-Cerinic M, Denton C, Launay D, Hachulla E; EUSTAR Collaborators. Collaborators (248) **Farge D**. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. *Arthritis Rheumatol*. 2019 Sep;71(9):1553-1570. doi: 10.1002/art.40906. Epub 2019 Aug 12.

--Golemi I, Cote L, Iftikhar O, Brenner B, Tafur A, Bikdeli B, Fernández-Capitán C, Pedrajas JM, Otero R, Quintavalla R, Monreal M; Registro Informatizado de Enfermedad Tromboembólica Investigators. Collaborators (112) **Farge-Bancel D**. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry. *J Vasc Surg Venous Lymphat Disord*. 2019 Nov 26. pii: S2213-333X(19)30236-7. doi: 10.1016/j.jvsv.2019.03.011. [Epub ahead of print]

--Mellado M, Trujillo-Santos J, Bikdeli B, Jiménez D, Núñez MJ, Ellis M, Marchena PJ, Vela JR, Clara A,

Moustafa F, Monreal M; RIETE Investigators. Collaborators (162) **Farge-Bancel D**. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. *Intern Emerg Med*. 2019 Nov 27. doi: 10.1007/s11739-019-02242-w. [Epub ahead of print]

Filion, Kristian

--Garfinkle R, **Filion KB**, Bhatnagar S, Sigler G, Banks A, Letarte F, Liberman S, Brown CJ, Boutros M. Prediction model and web-based risk calculator for postoperative ileus after loop ileostomy closure. *Br J Surg*. 2019 Nov;106(12):1676-1684.

--Garfinkle R, Savage P, Boutros M, Landry T, Reynier P, Morin N, Vasilevsky CA, **Filion KB**. Incidence and predictors of postoperative ileus after loopileostomy closure: a systematic review and meta-analysis. *Surg Endosc* 2019;33:2430-2443.

--Lefebvre C, Zappitelli M, Hindié J, Platt RW, **Filion KB**. Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care. *Clin Kid J* 2019 May 20. sfz054, <https://doi.org/10.1093/ckj/sfz054>.

--Douros A, Durand M, Doyle CM, *Yoon S, Reynier P, **Filion KB**. Comparative effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis of observational studies. *Drug Saf* 2019;42:1135-1148.

--Douros A, Renoux C, Yin H, **Filion KB**, **Suissa S**, Azoulay L. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation. *Am J Med*. 2019 Feb;132(2):191-199.

Filion KB, Douros A, Azoulay L, Yin H, **Yu O**, **Suissa S**. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: a population-based cohort study. *Br J Clin Pharmacol* 2019; 85:2378-2389.

--**Filion KB**, **Yu OH**. Sodium-glucose cotransporter 2 inhibitors and severe urinary tract infections: reassuring real-world evidence. *Ann Intern Med* 2019; 171(4):289-290. [Invited Editorial].

--Grandi SM, **Filion KB**, *Yoon S, *Ayele HT, Doyle CM, Hutcheon JA, Smith GN, Gore GC, Ray JG, Nerenberg K, Platt RW. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications. *Circulation* 2019;139:1069-1079.

--Huang TY, Welch EC, Shinde MU, Platt RW, **Filion KB**, Azoulay L, Maro MC, Platt R, Toh S. Reproducing Protocol-based Studies Using Parameterizable Tools - Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks. *ClinPharmacolTher* 2019 Oct 20. doi: 10.1002/cpt.1698. [Epub ahead of print].

--Khosrow-Khavar F, Kurteva S, Cui Y, **Filion KB**, Douros A. Opioids and the risk of infection: a critical appraisal of the pharmacologic and clinical evidence. *Expert Opin Drug Meta Toxicol*. 2019 Jul; 15(7): 565-575.

--Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, **Filion KB**, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttman A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. Directives pour l'évaluation des études réalisées à partir des données de santé collectées en routine en pharmacoépidémiologie : RECORD-PE (REporting of studies Conducted using Observational Routinely-collected health Data for pharmacoepidemiology) *CMAJ* 2019; 24;191:E689-E708. [published in French].

--Lancione S, **†Wade K, Windle SB, **Filion KB**, **Thombs BD**, **Eisenberg MJ**. Non-medical cannabis in North America: an overview of regulatory approaches. *Public Health* 2019 Oct 7;178:7-14.

--Oh IS, **Filion KB**, Jeong HE, Shin JY. An empirical assessment of immeasurable time bias in the setting of

nested case-control studies: statins and all-cause mortality among patients with heart failure. *Pharmacoepidemiol Drug Saf* 2019;28: 1318-1327.

Foulkes, William D.

--Metcalf K, Lynch HT, **Foulkes WD**, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. *Br J Cancer*. 120(4):398-403. 2019.

--Xue Y, Meehan B, Fu Z, Wang XQD, Fiset P-O, Rieker R, Levins C, Kong T, Zhu X, Morin G, Skerritt L, Herpel E, Venneti S, Martinez D, Judkins AR, Jung S, Camilleri-Broet S, Gonzalez A-V, Guiot M-C, Lockwood W, Spicer J, Agaimy A, Pastor W, Dostie J, Rak J, **Foulkes WD**, Huang S. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. *Nat Commun*. 10(1):557. 2019.

--Xue Y, Meehan B, Macdonald E, Venneti S, Wang X-Q, Witkowski L, Jelincic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson R, Cencic R, Patibandla J, Chen H, Papadakis A, Auguste A, de Rink I, Kerkhoven R, Bertos N, Gotlieb W, Clarke B, Leary A, Witcher M, Guiot M-C, Pelletier J, Dostie J, Park M, Judkins A, Hass R, Levine D, Rak J, Vanderhyden B, **Foulkes WD***, and Huang S. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. *Nat Commun*. 10(1):558. 2019.

--Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, Ligtenberg MJL, Vos JR, Ten Broeke SW, de Miranda NFCC, Kuiper RA, Kamping EJ, Jansen EAM, Vink-Börger ME, Popp I, Lang A, Spier I, Hüneburg R, James PA, Li N, Staninova M, Lindsay H, Cockburn D, Spasic-Boskovic O, Clendenning M, Sweet K, Capellá G, Sijmensen W, Høberg-Vetti H, Jongmans MC, Neveling K, Geurts van Kessel A, Morreau H, Hes FJ, Sijmons RH, Schackert HK, Ruiz-Ponte C, Dymerska D, Lubinski J, Rivera B, **Foulkes WD**, Tomlinson IP, Valle L, Buchanan DD, Kenwick S, Adlard J, Dimovski AJ, Campbell IG, Aretz S, Schindler D, van Wezel T, Hoogerbrugge N, Kuiper RP. Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype. *Cancer Cell*. 35(2):256-266. 2019.

--Pejovic T, McCluggage WG, Krieg AJ, Xu F, Lee DM, Witkowski L, **Foulkes WD**. The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type. *Gynecol Oncol Rep*. 28:47-49. 2019.

--Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, **Foulkes WD**, Malkin D, Tabori U, Pearson CE. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. *J Clin Oncol*. 37(6):461-470. 2019.

--Fahiminiya S, Sabbaghian N, Albrecht S, Nadaf J, Callegaro-Filho D, **Foulkes WD**. Ovarian small cell carcinoma in one of a pair of monozygous twins. *Fam Cancer*. 18(2):161-163. 2019.

--Gallon R, Mühlegger B, Wenzel SS, Sheth H, Hayes C, Aretz S, Dahan K, **Foulkes W**, Kratz CP, Ripperger T, Azizi AA, Baris Feldman H, Chong AL, Demirsoy U, Florkin B, Imschweiler T, Januszkiewicz-Lewandowska D, Lobitz S, Nathrath M, Pander HJ, Perez-Alonso V, Perne C, Ragab I, Rosenbaum T, Rueda D, Seidel MG, Suerink M, Taeubner J, Zimmermann SY, Zschocke J, Borthwick GM, Burn J, Jackson MS, Santibanez-Koref M, Wimmer K. A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes. *Hum Mutat*. 40(5):649-655. 2019.

--Apellaniz-Ruiz M, Segni M, Kettwig M, Gluer S, Pelletier D, Nguyen VH, Wagener R, López C, Muchantef K, Bouron-Dal Soglio D, Sabbaghian N, Wu MK, Zannella S, Fabian MR, Siebert R, Menke J, Priest JR, **Foulkes WD**. Mesenchymal hamartoma of the liver and DICER1 syndrome. *N Engl J Med*. 380(19):1834-1842.

2019.

--Shorstova T, Marques M, Su J, Johnston J, Kleinman CL, Hamel N, Huang S, Alaoui-Jamali MA, **Foulkes WD**, Witcher M. SWI/SNF-compromised cancers are susceptible to bromodomain inhibitors. *Cancer Res.* 79(10):2761-2774. 2019.

--Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, **Foulkes WD**, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat.* 175(2):443-449. 2019.

--**Foulkes WD**, Polak P. Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over. *Ann Oncol.* 30(7):1023-1025. 2019.

--Roussel L, Landekic M, Golizeh M, Gavino C, Zhong MC, Chen J, Faubert D, Blanchet-Cohen A, Dansereau L, Parent MA, Marin S, Luo J, Le C, Ford BR, Langelier M, King IL, Divangahi M, **Foulkes WD**, Veillette A, Vinh DC. [Loss of human ICOSL results in combined immunodeficiency.] *Med Sci (Paris).* 35(8-9):625-628. 2019.

--de Kock L, Hillmer M, Wagener R, Soglio DB, Sabbaghian N, Siebert R, Priest JR, Miller M, **Foulkes WD**. Further evidence that full gene deletions of DICER1 predispose to DICER1 syndrome. *Genes Chromosomes Cancer.* 58(8):602-604. 2019.

--Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L; kConFab Investigators, Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, **Foulkes WD**, Reis-Filho JS. Homologous recombination DNA repair defects in PALB2-associated breast cancers. *NPJ Breast Cancer.* 5:23. 2019.

--Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, ...48 authors alphabetical..., **Foulkes WD**, ...147 authors alphabetical..., Investigators K, Lázaro C, De Nicolo A, Radice P, Engel C, Schmutzler RK, Goldgar DE, Spurdle AB. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Hum Mutat.* 40(9):1557-1578. 2019.

--Guillerman RP, **Foulkes WD**, Priest JR. Imaging of DICER1 syndrome. *Pediatr Radiol.* 49(11):1488-1505. 2019. Review.

--Friebel TM, Andrulis IL, Balmaña J, Blanco AM, Couch FJ, Daly MB, Domchek SM, Easton DF, **Foulkes WD**, Ganz PA, Garber J, Glendon G, Greene MH, Hulick PJ, Isaacs C, Jankowitz RC, Karlan BY, Kirk J, Kwong A, Lee A, Lesueur F, Lu KH, Nathanson KL, Neuhausen SL, Offit K, Palmero EI, Sharma P, Tischkowitz M, Toland AE, Tung N, van Rensburg EJ, Vega A, Weitzel JN; GEMO Study Collaborators, Hoskins KF, Maga T, Parsons MT, McGuffog L, Antoniou AC, Chenevix-Trench G, Huo D, Olopade OI, Rebbeck TR. BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry. *Hum Mutat.* 40(10):1781-1796. 2019.

--Glentis S, Dimopoulos AC, Rouskas K, Ntrisots G, Evangelou E, Narod SA, Mes-Masson AM, **Foulkes WD**, Rivera B, Tonin PN, Ragoussis J, Dimas AS. Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer. *Front Genet.* 10:1005. 2019.

--Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM; ABCTB Investigators, ... 80 authors alphabetical..., **Foulkes WD**, ...157 authors alphabetical..., Dunning AM, Lush M, Wang Q, McGuffog L, Parsons MT, Pharoah PDP, Fostira F, Toland AE, Andrulis IL, Ramus SJ, Swerdlow AJ, Greene MH, Chung WK, Milne RL, Chenevix-Trench G, Dörk T, Schmidt MK, Easton DF, Radice P, Hahnen E, Antoniou AC, Couch FJ, Nevanlinna H,

Surrallés J, Peterlongo P. The FANCM:p. Arg658* truncating variant is associated with risk of triple-negative breast cancer. *NPJ Breast Cancer*. 5:38. 2019.

--Kong T, Xue Y, Cencic R, Zhu X, Monast A, Fu Z, Pilon V, Sangwan V, Guiot MC, **Foulkes WD**, Porco JA Jr, Park M, Pelletier J, Huang S. eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. *Mol Cancer Ther*. 18(11):2158-2170. 2019.

--de Kock L, Wu MK, **Foulkes WD**. Ten years of DICER1 mutations: Provenance, distribution, and associated phenotypes. *Hum Mutat*. 40(11):1939-1953. 2019.

--Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, ... 46 authors..., **Foulkes WD**, ... 80 authors..., Dudderidge T; IMPACT Study Collaborators, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *Eur Urol*. 76(6):831-842. 2019.

Friedman, Gad

--Heron V, Golden C, Blum S, **Friedman G**, Galiasatos P, **Hilzenrat N**, Stein BL, Szilagyi A, Wyse J, Batta R and Cohen A. Endoscopist-directed propofol as an adjunct to standard sedation: a Canadian experience. *Journal of the Canadian Association of Gastroenterology* 2019; 20: 1-4. doi: 10. 1093/jcag/gwz011.

Gatignol, Anne

--Goguen RP, Malard CMG, Scarborough RJ, **Gatignol A**. Small RNAs to treat human immunodeficiency virus type 1 infection by gene therapy. 2019. *Curr. Open. Virol*. 38:10-20

--Scarborough RJ, Goguen RP, **Gatignol A**. A second patient cured of HIV infection: hopes and limitations. 2019. *Virologie*. 23:1-4.

--Del Corpo O, Goguen RP, Malard CMG, Daher A, Colby-Germinario S, Scarborough RJ, **Gatignol A**. A U1i RNA that enhances HIV-1 splicing with elongated recognition domain is an optimal candidate for combination HIV-1 gene therapy. *Mol. Ther. Nucleic Acids*. 2019. 18:815-830.

Goldfarb, Michael

--**Goldfarb M, Afilalo J**. Cardiac rehabilitation: Are we Missing an Important Means to Defrail and Reverse Adverse Consequences of Aging? *Can J Cardiol*. 2020. Epublished in 2019, <https://doi.org/10.1016/j.cjca.2019.11.037>.

--Dima D, Valiquette J, Berube-Dufour J, **Goldfarb M**. Level of Function Mobility Scale for Nurse-Driven Early Mobilization in Patients with Acute Cardiovascular Disease. *J Clin Nurs*. 2019;00:1–7. <https://doi.org/10.1111/jocn.15124>

--Woolridge S, Alemayehu W, Kaul P, Fordyce CB, Lawler PR, Lemay M, Jentzer J, **Goldfarb M**, Wong G, Armstrong P, van Diepen S. National trends in coronary intensive care unit admissions, resource utilization, and outcomes. *Eur Heart J Acute Cardiovasc Care*. 2019;2048872619883400.

--Herscovici R, Mirocha J, Salomon J, Merz NB, Cercek B, **Goldfarb M**. Sex differences in crude mortality rates and predictive value of intensive care unit-based scores when applied to the cardiac intensive care unit. *Eur Heart J Acute Cardiovasc Care*. 2019; 2048872619872129.

--**Goldfarb M**, Marcano Y, Schafer D, Chronopoulos J, Hayman V, Trnkus A and **Afilalo J**. Dietary protein intake in older adults undergoing cardiac surgery. *Nutr Meta Cardiovasc Dis*. 2019;29:1095-1100.

--Bibas L, Peretz-Larochelle M, Adhikari NK, **Goldfarb MJ**, Luk A, Englesakis M, Detsky ME and Lawler PR. Association of Surrogate Decision-making Interventions for Critically Ill Adults With Patient, Family, and Resource Use Outcomes: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2019;2:e197229.

Greenaway, Christina

--Asundi A, Beliavsky A, Liu XJ, Akaberi A, Schwarzer G, Bisoffi Z, Requena-Méndez A, Shrier I, **Greenaway C***. Prevalence of strongyloidiasis and schistosomiasis among migrants: A systematic review and meta-analysis. *Lancet Glob Health*. 2019 Feb;7(2):e236-e248. doi: 10.1016/S2214-109X(18)30490-X.

--**Greenaway C***, Castelli F. Migration Medicine. *Infectious Diseases Clinics of North America*. 2019 Mar;33(1):265-287. doi: 10.1016/j.idc.2018.10.014.

--**Greenaway C***, Castelli F. Embracing the challenges of migration medicine. Editorial. *J Travel Med* 2019 Feb 1;26(2). pii: taz009. doi: 10.1093/jtm/taz009.

--**Greenaway C***, Castelli F. Infectious diseases at different stages of migration: an expert review. *J Travel Med*. 2019 Feb 1;26(2). pii: taz007. doi: 10.1093/jtm/taz007

--Heywood A, Castelli F, **Greenaway C**. Migration Health: highlights from inaugural International Society of Travel Medicine (ISTM). *Current Infectious Disease Reports*. 2019 Nov 16;21(12):48. doi: 10.1007/s11908-019-0705-6.

Hilzenrat, Nir

Heron V, Golden C, Blum S, **Friedman G**, Galiasatos P, **Hilzenrat N**, Stein BL, Szilagyi A, Wyse J, Batta R and Cohen A. Endoscopist-directed propofol as an adjunct to standard sedation: a Canadian experience. *Journal of the Canadian Association of Gastroenterology* 2019; 20: 1-4. doi: 10.1093/jcag/gwz011

Hirsch, Andrew

--Helmersen D, Provencher S, **Hirsch AM**, Van Dam A, Dennie C, De Perrot M, Mielniczuk L, Hirani N, Chandy G, Swiston J, Lien D, Kim NH, Delcroix M, Mehta S. Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update, *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*. 2019; 3(4): 177-198, DOI: 10.1080/24745332.2019.1631663.

--Kearon C, de Wit K, Parpia S, Schulman S, Afilalo M, **Hirsch A**, Spencer FA, Sharma S, D'Aragnon F, Deshaies J-F, Le Gal G, Lazo-Langner A, Wu C, Rudd-Scott L, Bates SM, Julian JA, for the PeGeD Study Investigators. Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability. *N Engl J Med*. 2019;381(22):2125-2134.

Hudson, Marie

--Thombs BD, Aguila K, Dyas L, Carrier ME, Fedoruk C, Horwood L, Canedo-Ayala M, Sauve M, Kwakkenbos L, Malcarne VL, El-Baalbaki G, Pelaez S, Connolly K, **Hudson M**, Platt RW. Protocol for a partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader EDUCation (SPIN-SSLED) Program. *Trials* 2019;20:717.

--Taualii M, Davis EL, Braun KL, Tsark JU, Brown N, **Hudson M**, Burke W. Correction to: Native Hawaiian Views on Biobanking. *Journal of cancer education: the official journal of the American Association for Cancer Education* 2019. --Montastruc

--Thombs BD, Dyas L, Pepin M, Aguila K, Carrier ME, Tao L, Harb S, Malcarne VL, El-Baalbaki G, Pelaez S, Sauve M, **Hudson M**, Platt RW. Scleroderma Patient-centered Intervention Network-Scleroderma Support group Leader EDUCation (SPIN-SSLED) program: non-randomised feasibility trial. *BMJ open* 2019;9:e029935.

--Lu T, Klein KO, Colmegna I, Lora M, Greenwood CMT, **Hudson M**. Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis. *BMC medical genomics* 2019;12:144.

--Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, **Hudson M**, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH. Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. *Nature Communications*,10:4712. doi: 10. 1038/s41467-019-12628-1. 2019.

--Puyade M, Maltez N, Lansiaux P, Pugno G, Roblot P, Colmegna I, **Hudson M**, Farge D. Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review. *Rheumatology (Oxford, England)* 2019.

--Shao X, **Hudson M**, Colmegna I, Greenwood CMT, Fritzler MJ, Awadalla P, Pastinen T, Bernatsky S. Rheumatoid arthritis-relevant DNA methylation changes identified in ACPA-positive asymptomatic individuals using methylome capture sequencing. *Clinical epigenetics* 2019;11:110.

--Qendro T, de la Torre ML, Panopalis P, Hazel E, Ward BJ, Colmegna I, **Hudson M**. Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. *The Journal of rheumatology* 2019.

--Jamal S, **Hudson M**, Fifi-Mah A, Ye C. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. *The Journal of rheumatology* 2019.

--**Hudson M**, Dell'Aniello S, Shen S, Simon TA, **Ernst P**, Suissa S. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. *Rheumatology (Oxford)*. 2019 Sep 3. [Epub ahead of print].

--Ferdowsi N, Huq M, Stevens W, **Hudson M**, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, **Baron M**, Nikpour M. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. *Annals of the rheumatic diseases* 2019;78:807-16.

--Kim H, Levy DM, Silverman ED, Hitchon C, Bernatsky S, Pineau C, Smith CD, Tucker L, Petty R, Arbillaga H, Zummer M, **Hudson M**, Fortin P, Huber AM, Chedeville G, Peschken C, Pope JE. A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. *Rheumatology (Oxford, England)* 2019.

--Montastruc F, Renoux C, **Hudson M**, Dell'Aniello S, Simon TA, Suissa S. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. *Seminars in arthritis and rheumatism* 2019;48:1053-8.

--Maliha PG, **Hudson M**, Abikhzer G, Singerman J, Probst S. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications. *Nuclear medicine communications* 2019;40:377-82.

--Esfahani K, Meti N, Miller WH, Jr. , **Hudson M**. Adverse events associated with immune checkpoint inhibitor treatment for cancer. *CMAJ : Canadian Medical Association journal*, 2019;191:E40-46.

--Montastruc F, Renoux C, Dell'Aniello S, Simon TA, Azoulay L, **Hudson M**, Suissa S. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. *Rheumatology (Oxford, England)* 2019;58:683-91.

--Richard N, **Hudson M**, Wang M, Gyger G, Proudman S, Stevens W, Nikpour M, **Baron M**. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. *Rheumatology (Oxford, England)* 2019;58:636-44.

--Ishihara M, Harel D, Levis B, Levis AW, Riehm KE, Saadat N, Azar M, Rice DB, Sanchez TA, Chiovitti MJ, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Arroll B, Bombardier CH, Butterworth P, Carter G, Clover K, Conwell Y, Goodyear-Smith F, Greeno CG, Hambridge J, Harrison PA,

Hudson M, Jette N, Kiely KM, McGuire A, Pence BW, Rooney AG, Sidebottom A, Simning A, Turner A, White J, Whooley MA, Winkley K, Benedetti A, Thombs BD. Shortening self-report mental health symptom measures through optimal test assembly methods: Development and validation of the Patient Health Questionnaire-Depression-4. *Depression and anxiety* 2019;36:82-92.

--Peschken CA, Wang Y, Abrahamowicz M, Pope J, Silverman E, Sayani A, Iczkovitz S, Ross J, Zummer M, Tucker L, Pineau C, Levy D, **Hudson M**, Hitchon CA, Huber AM, Smith CD, Avina-Zubieta A, Arbillaga H, Chedeville G, Wynant W, Fortin PR. Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. *The Journal of rheumatology* 2019;46:166-75.

--Becetti K, Kwakkenbos L, Carrier ME, Gordon JK, Nguyen JT, Mancuso CA, Mouthon L, Nguyen C, Rannou F, Welling J, Thombs BD, Spiera RF; SPIN Investigators (including **Hudson M**). Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. *J Rheumatol.* 2019 Dec;46(12):1605-1613.

--Harel D, Mills SD, Kwakkenbos L, Carrier ME, Nielsen K, Portales A, Bartlett SJ, Malcarne VL, **Thombs BD**; and the SPIN Investigators (including **Hudson M**). Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. *BMJ Open.* 2019 Feb 22;9(2):e024010.

--Harrison M, Spooner L, Bansback N, Milbers K, Koehn C, Shojania K, Finckh A, **Hudson M**. Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals. *PLoS One.* 2019 Apr 25;14(4):e0216075.

--Kwakkenbos L, Cumin J, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Rannou F, Welling J, **Thombs BD**, SPIN Investigators (includes **Hudson M**). Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. *BMJ Open* 2019 Oct 14;9(10):e029542.

Jagoe, Thomas

--Nasrah R, Van Der Borch C, Kanbalian M, **Jagoe RT**. Defining barriers to implementation of nutritional advice in patients with cachexia [published online ahead of print, 2019 Aug 21]. *J Cachexia Sarcopenia Muscle.* 2019;10. 1002/jcsm. 12490.

Johnson, Nathalie

--Esfahani K, Buhlaiga N, Thébault P, Lapointe R, **Johnson NA, Miller WH Jr**. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. *New England Journal of Medicine*, 380(24): 2375-2376, 2019.

Kahn, Susan

--Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, **Kahn SR**, Rahman M, Rajasekhar A, Rogers FB, Smythe MA, Tikkinen KAO, Yates AJ, Baldeh T, Balduzzi S, Brozek JL, Ikobaltzeta IE, Johal H, Neumann I, Wiercioch W, Yepes-Nuñez JJ, Schünemann HJ, Dahm P. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood Adv.* 2019 Dec 10;3(23):3898-3944.

--Magnuson EA, Chinnakondepalli K, Vilain K, Kearon C, Julian JA, **Kahn SR**, Goldhaber SZ, Jaff MR, Kindzelski AL, Herman K, Brady PS, Sharma K, Black CM, Vedantham S, Cohen DJ. Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial. *Circ Cardiovasc Qual Outcomes* 2019;12(10):e005659.

--**Kahn SR**, Diendéré G, Morrison DR, Piché A, Filion KB, Klil-Drori AJ, Douketis JD, Emed J, Roussin A, **Tagalakis V**, Morris M, Geerts W. The effectiveness of interventions for the implementation of

thromboprophylaxis in hospitalized patients at risk for venous thromboembolism: an updated abridged Cochrane systematic review and meta-analysis of Randomized Controlled Trials (RCT). *BMJ Open* 2019 9(5) e024444.

--Kearon C, Gu CS, Julian JA, Goldhaber SZ, Comerota AJ, Gornik HL, Murphy TP, Lewis L, **Kahn SR**, Kindzelski AL, Slater D, Geary R, Winokur R, Natarajan K, Dietzek A, Leung DA, Kim S, Vedantham S. Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral-Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial. *Thromb Haemost* 2019 Apr;119(4):633-644.

--Righini M, Robert-Ebadi H, Glauser F, Blondon M, Ouvry P, Diamand JM, Tissot A, Frappe P, Quere I, **Kahn SR**, Galanaud JP, Le Gal G. Effect of anticoagulant treatment on pain in distal deep vein thrombosis: an ancillary analysis from the cactus trial. *J Thromb Haemost* 2019 Mar;17(3):507-510.

--Comerota AJ, Kearon C, Gu CS, Julian JA, Goldhaber SZ, **Kahn SR**, Jaff MR, Razavi MK, Kindzelski AL, Bashir R, Patel P, Sharafuddin M, Sichlau MJ, Saad WE, Assi Z, Hofmann LV, Kennedy M, Vedantham S; ATTRACT Trial Investigators. Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis: Analysis from a Stratified Multicenter Randomized Trial. *Circulation* 2019 Feb 26;139(9):1162-1173.

--Ni J, Dasgupta K, **Kahn SR**, Talbot D, Lefebvre G, Lix LM, Berry G, Burman M, Dimentberg R, Laflamme Y, Cirkovic A, Rahme E. Comparing external and internal validation methods in correcting outcome misclassification bias in logistic regression: A simulation study and application to the case of postsurgical venous thromboembolism following total hip and knee arthroplasty. *Pharmacoepidemiol Drug Saf* 2019 Feb;28(2):217-226.

Koolian, Maral

--Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, **Brenner B**, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; (**Koolian M**); (**Tagalakis V**); International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol*. 2019 Oct;20(10):e566-581.

Langleben, David

--Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, Kawut SM, **Langleben D**, Lumens J, Naeije R. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. *Eur Respir J*. 2019 Jan 24;53: 1801900.

--**Langleben D**, Orfanos SE, Giovinazzo M, Schlesinger RD, Naeije R, Fox BD, Abualsaud AO, Blenkhorn F, Rudski LG, Catravas JD. Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. *Am J Physiol Lung Cell Mol Physiol*. 2019;317:L361-L368.

Larouche, Vincent

--Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S. Treatment Options for Pancreatic Neuroendocrine Tumors. *Cancers (Basel)*. 2019 Jun 14;11(6). pii: E828. doi: 10.3390/cancers11060828.

--**Larouche V**, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. *Cancers (Basel)*. 2019 Sep 18;11(9). pii: E1395. doi: 10.3390/cancers11091395.

--**Larouche V**, Akirov A, Thain E, Kim RH, Ezzat S. Co-occurrence of breast cancer and neuroendocrine tumours: New genetic insights beyond Multiple Endocrine Neoplasia syndromes. *Endocrinol Diabetes Metab*. 2019 Sep 8;2(4):e00092. doi: 10.1002/edm2.92. eCollection 2019 Oct.

--Akirov A, Asa SL, **Larouche V**, Mete O, KSawka AM, Jang R, Ezzat S. The Clinico-pathological Spectrum of Parathyroid Carcinoma. *Front Endocrinol (Lausanne)*. 2019 Oct 23;10:731. doi: 10.3389/fendo.2019.00731. eCollection 2019.

--**Larouche V**, Akirov A, Thomas CM, Krzyzanowska MK and Ezzat S. A Primer on the Genetics of Medullary Thyroid Cancer. *Current Oncology*. 2019 December; 26(6).

Leclair, Valery

--**Leclair V**, Landon-Cardinal O, **Hudson M**. Letter in response to 'Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors'. *European journal of cancer (Oxford, England : 1990)* 2019;112:47-8.

--**Leclair V**, Svensson J, Lundberg IE, Holmqvist M. Acute Coronary Syndrome in Idiopathic Inflammatory Myopathies: A Population-based Study. *The Journal of rheumatology* 2019;46:1509-14.

--**Leclair V**, Galindo-Feria AS, Dastmalchi M, Holmqvist M, Lundberg IE. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. *Rheumatology (Oxford, England)* 2019;58:1214-20.

--**Leclair V**, Lundberg IE, Tjarnlund A. Response to: 'Time to personalise the treatment of anti-MDA-5 associated lung disease' by Lake et al. *Annals of the rheumatic diseases* 2019;78:e53.

Lipman, Mark

--Hassani-Ardakania K, **Lipman ML**, Laporta D, Yu OHY. A case of severe acute kidney injury exacerbated by canagliflozin in a patient with type 2 diabetes. *Case reports in Endocrinology*. 2019 Jun 4. doi: 10.1155/2019/8639629.

Liang, Chen

--Hu S, Sun H, Yin L, Li J, Mei S, Xu F, Wu C, Liu X, Zhao F, Zhang D, Huang Y, Ren L, Cen S, Wang J, **Liang C**, Guo F. PKR-dependent cytosolic cGAS foci are necessary for intracellular DNA sensing. *Sci Signal*. 2019 Nov 26;12(609). pii: eaav7934. doi: 10.1126/scisignal.aav7934.

--Zhu M, Ma L, Wen J, Dong B, Wang Y, Wang Z, Zhou J, Zhang G, Wang J, Guo Y, **Liang C**, Cen S, Wang Y. Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase. *European Journal of Medicinal Chemistry*. 2019;185:111900.

--Zhu M, Ma L, Zhou H, Dong B, Wang Y, Wang Z, Zhou J, Zhang G, Wang J, **Liang C**, Cen S, Wang Y. Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants. *European Journal of Medicinal Chemistry*. 2019; 185 (online 2019/11).

--Wang J, Zhang Y, Li Q, Zhao J, Yi D, Ding J, Zhao F, Hu S, Zhou J, Deng T, Li X, Guo F, **Liang C**, Cen S. Influenza Virus Exploits an Interferon-Independent lncRNA to Preserve Viral RNA Synthesis through Stabilizing Viral RNA Polymerase PB1. *Cell Reports* 2019;27(11): 3295-3304.

--Beitari S, Wang Y, Liu SL, **Liang C**. HIV-1 Envelope Glycoprotein at the Interface of Host Restriction and Virus Evasion. *Viruses* 2019;11(4).

--Yu J, **Liang C**, Liu SL. CD4-dependent Modulation of HIV-1 Entry by LY6E. *Journal of Virology* 2019;93. JVI. 01866-18.

--Li J, Hu S, Xu F, Mei S, Liu X, Yin L, Zhao F, Zhao X, Sun H, Xiong Z, Zhang D, Cen S, Wang J, **Liang C**, Guo F. MOV10 sequesters the RNP of influenza A virus in the cytoplasm and is antagonized by viral NS1 protein. *Biochemical Journal*. 2019;476. BCJ20190754.

Lin, Rongtuan

--Cao L, Liu S, Li Y, Yang G, Luo Y, Li S, Du H, Zhao Y, Wang D, Chen J, Zhang Z, Li M, Ouyang S, Gao X, Sun Y, Wang Z, Yang L, **Lin R**, Wang P, You F. The Nuclear Matrix Protein SAFA Surveils Viral RNA and Facilitates Immunity by Activating Antiviral Enhancers and Super-enhancers. *Cell Host Microbe*. 2019 Sep 11;26(3):369-384. doi:10.1016/j.chom.2019.08.010.

--Huang B, Huang S, Chen X, Liu XB, Wu Q, Wang Y, Li X, Li K, Gao H, Cen S, **Lin R**, Liu Z, Jin X. Activation of Mast Cells Promote Plasmodium berghei ANKA Infection in Murine Model. *Front Cell Infect Microbiol*. 2019 Sep 10;9:322. doi: 10.3389/fcimb.2019.00322. eCollection 2019.

--Acchioni C, Remoli AL, Marsili G, Acchioni M, Nardolillo I, Orsatti R, Farcomeni S, Palermo E, Perrotti E, Barreca ML, Sabatini S, Sandini S, Parolin C, **Lin R**, Borsetti A, Hiscott J, Sgarbanti M. Alternate NF- κ B independent signaling re-activation of latent HIV-1 provirus. *J Virol*. 2019 Jun 26. pii: JVI.00495-19. doi: 10.1128/JVI.00495-19. [Epub ahead of print].

--Chang NS, **Lin R**, Sze CI, Aqeilan RI. Editorial: WW Domain Proteins in Signaling, Cancer Growth, Neural Diseases, and Metabolic Disorders. *Front Oncol*. 2019 Aug 2;9:719. doi: 10.3389/fonc.2019.00719. eCollection 2019.

Lipes, Jed

--Huard P, Kalavrouziotis D, **Lipes J**, Simon M, Tardif MA, Blackburn S, Langevin S, Sia YT, Mohammadi S. Does the full-time presence of an intensivist lead to better outcomes in the cardiac surgical intensive care unit? *J Thorac Cardiovasc Surg*. 2019 May 11. pii: S0022-5223(19)30976-6. doi: 10.1016/j.jtcvs.2019.03.124. [Epub ahead of print].

MacNamara, Elizabeth

--Srinivasan Sridhar V, Chen M, Gerson H, **MacNamara E**, **Nessim SJ**. Variation of High-Sensitivity Troponin T Results in Patients Undergoing Continuous Renal Replacement Therapy. *Can J Kidney Health Dis*. 2019 Feb 15;6:2054358119828386. doi: 10.1177/2054358119828386. eCollection 2019.

--Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylett RJ. The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. *Can J Neurol Sci*. 2019 Sep;46(5):499-511. doi: 10.1017/cjn.2019.27. Epub 2019 Jul 16.

Mamane, Samuel

--**Mamane S**, Mullie L, Lok Ok Choo W, Piazza N, Martucci G, Morais JA, Kim DH, Lauck S, Webb JG, **Afilalo J**; FRAILTY-AVR Investigators. Sarcopenia in Older Adults Undergoing Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol*. 2019 Dec 24;74(25):3178-3180. doi: 10.1016/j.jacc.2019.10.030.

Mann, Koren

--Wu TH, Bolt AM, Chou H, Plourde D, De Jay N, Guilbert C, Young YK, Kleinman CL, **Mann KK**. Tungsten Blocks Murine B Lymphocyte Differentiation and Proliferation Through Downregulation of IL-7 Receptor/Pax5 Signaling. *Toxicol Sci*. 2019 Jul 1;170(1):45-56. doi: 10.1093/toxsci/kfz080.

Mardigyan, Vartan

--Imazio M, Andreis A, De Ferrari GM, Cremer PC, **Mardigyan V** et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. *Eur J Prev Cardiol*. 2019 Oct 15:2047487319879534 [Epub ahead of print].

--Roncero C, **Mardigyan V**, Service E, Singerman J, Whittaker KC, Friedman M, Chertkow H. Investigation into the effect of transcranial direct current stimulation on cardiac pacemakers. *Brain Stimul*. 2020 Jan -

Feb;13(1):89-95. Epub 2019 Aug 17.

Mesplede, Thibault

--Han Y, Pham HT, Xu H, Quan Y, **Mesplède T**. Antimalarial drugs and their metabolites are potent Zika virus inhibitors. *J Med Virol*. 2019; 91:1182-1190. doi: 10. 1002/jmv. 25440. Epub 2019 Mar 4.

--Pham HT, **Mesplède T**. Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. *Expert Opin Pharmacother*. 2019; 20:385-397. doi: 10. 1080/14656566. 2018. 1560423. Epub 2019 Jan 30. Review.

--Van Rompay KKA, Hassounah S, Keele BF, Lifson JD, Ardeshir A, Watanabe J, Pham HT, Chertova E, Sowder R, Balzarini J, **Mesplède T**, Wainberg MA. Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes. *J Virol*. 2019; 4;93(2). pii: e01189-18. doi: 10. 1128/JVI. 01189-18. Print 2019 Jan 15.

Miller, Wilson H. Jr.

--Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, Belanger K, **Miller WH Jr**, Jamal R, Letarte N, Wong P and Routy B. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. *OncoImmunology*. 8(4),1-6, 2019.

--Guo Q, Huang F, Goncalves C, Del Rincón SV, **Miller WH Jr**. Translation of cancer immunotherapy from the bench to the bedside. *Adv Cancer Res*, 143:1-62, 2019.

--Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, **Miller WH Jr**. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. *Cancer Research*. 79(7):1646-1657, 2019.

--Hellmann MD, Kim TW, Lee CB, Goh BC, **Miller WH**, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. *Annals of Oncology*. 30,(7):1134–1142, 2019.

--Kumar R, Van de Vijver M, Tortora G, Ciardiello F, Tzipora Goldkorn, **Miller WH Jr**, and Norton L. A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. *Cancer Research*, DOI: 10. 1158/0008-5472. CAN-19-0989, 2019.

--Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, **Miller WH Jr**, Gurney H, Berger R, Schmidinger M, Larkin J, Atkins MB, Bedke J, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Huang B, Di Pietro A and Choueiri TK. Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. *NEJM*. 380:1103-1115, 2019.

--Razak AR, **Miller WH Jr**, Uy GL, Blotner S, Young AM and Higgins B, Chen LC and Gore L. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. *Investigational New Drugs Journal*. <https://doi.org/10.1007/s10637-019-00869-2>, 2019.

--Ribas A, Lawrence D, Atkinson V, Agarwal S, **Miller WH Jr**, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Qing Zhao Q, Ghorri R, B Homet Moreno, Ibrahim N and Hamid O. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. *Nature Medicine*. 25(8), 1319, 2019.

--Rodon J, Soria JC, Berger R, **Miller WH Jr**, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Genomic and transcriptomic profiling expands

precision cancer medicine: the WINTHER trial. *Nature Medicine*. 25(5):751-758, 2019.

Monette, Johanne

--Puts MTE, Hsu T, Mariano C, **Monette J**, Brennenstuhl S, Pitters E, Ray J, Wan-Chow-Wah D, Kozlowski N, Krzyzanowska M, Amir E, Elser C, Jang R, Prica A, Krahn M, Beland F, Bergman S, Koneru R, Lemonde M, Szumacher E, Zidulka J, Fung S, Li A, Emmenegger U, Mehta R, Flemming K, Breunis H, Alibhai SMH. Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer-the 5C study: a study protocol for a randomised controlled phase III trial. *BMJ Open*. 2019 May 10;9(5):e024485. doi: 10. 1136/bmjopen-2018-024485.

--Sattar S, Alibhai SMH, Brennenstuhl S, Kulik M, MacDonald ME, McWatters K, Lee K, Jang R, Amir E, Krzyzanowska MK, Joshua AM, **Monette J**, Wan-Chow-Wah D, Puts MTE. Health status, emergency department visits, and oncologists' feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial. *J Geriatr Oncol*. 2019 Jan;10(1):169-174. doi: 10. 1016/j. jgo. 2018. 06. 014. Epub 2018 Jul 21.

Morais, Jose

--Montero-Odasso M, Almeida QJ, Bherer L, Burhan AM, Camicioli R, Doyon J, Fraser S, Muir-Hunter S, Li K, Liu-Ambrose T, McIlroy W, Middleton L, **Morais JA**, Sakurai R, Speechley M, Vasudev A, **Bauchet O**, Hausdorff J, Rosano C, Studenski S, Verghese J, and the Canadian Gait and Cognition Network. Canadian Consensus on Measures in Mobility and Cognition: From the Canadian Consortium on Neurodegeneration in Aging (CCNA). *J Gerontol A Biol Sci Med Sci*. 2019 May 16;74(6):897-909. doi: 10. 1093/gerona/gly148.

--Carvalho LP, Pion CH, Boutros GH, Gaudreau P, Chevalier S, Bélanger M, **Morais JA**, Aubertin-Leheudre M. Effect of a 12-week mixed power training on physical function in dynapenic-obese older men: Does severity of dynapenia matter? *Aging Clin Exp Res*. 2019 Jul;31(7):977-984. doi: 10. 1007/s40520-018-1048-0

--El-Hajj GB, **Morais JA**, Karelis A. Current concepts in healthy aging and physical activity: a viewpoint. *J Aging Physical Activity* 2019 Mar 27:1-7. doi: 10. 1123/japa. 2018-0208.

--Buckinx F, Gaudreau P, Marcangeli V, Boutros GEH, Dulac MC, **Morais JA**, Aubertin-Leheudre M. Muscle adaptation in response to a high-intensity interval training in obese older adults: effect of daily protein intake distribution. *Aging Clin Exp Res*. 2019 Jun;31(6):863-874. doi: 10. 1007/s40520-019-01149-y.

--Sonjak V, Jacob KW, Spendiff S, Vuda M, Perez A, Miguez K, Minozzo FC, Spake C, **Morais JA**, Hepple RT. Reduced Mitochondrial Content, Elevated ROS and Modulation by Denervation in Skeletal Muscle of Pre-frail/Frail Elderly Women. *J Gerontol A Biol Sci Med Sci*. 2019 Mar 11. pii: glz066. doi: 10. 1093/gerona/glz066.

--Jacob KW, Chevalier S, Lamarche M, **Morais JA**. Leucine supplementation does not alter insulin sensitivity in pre-frail and frail older women following a resistance training protocol. *J Nutr*. 2019 Jun 1;149(6):959-967. doi: 10. 1093/jn/nxz038.

--Mate K, Abou-Sharkh A, **Morais JA**, Mayo N. Putting the best foot forward: Relationships between indicators of step quality and cadence in three gait vulnerable population. *Neuro Rehabilitation*. 2019;44(2):295-301. doi: 10. 3233/NRE-182595.

--Murphy J, Bacon SL, **Morais JA**, Tsoukas MA, Santosa S. Intra-abdominal Adipose Tissue Quantification by Alternative versus Reference Methods: A Systematic Review and Meta-Analysis. *Obesity (Silver Spring)*. 2019 Jul;27(7):1115-1122. doi: 10. 1002/oby. 22494

--Tessier AJ, Wing S, Rahme E, **Morais JA**, Chevalier S. New cut-points for the diagnosis of sarcopenia and dynapenia from the Canadian Longitudinal Study on Aging. *J Cachexia Sarcopenia Muscle* 2019 Oct;10(5):985-999. doi: 10. 1002/jcsm. 12462.

--Gosselin J, Béliveau J, Hamel M, Casa D, Hosokawa Y, **Morais JA**, Eric D. B. Goulet EDB. Wireless Measurement of Rectal Temperature During Exercise: Comparing an Ingestible Thermometric Telemetric Pill Used as a Suppository Against a Conventional Rectal Probe. *J Therm Biol.* 2019 Jul;83:112-118. doi: 10.1016/j.jtherbio.2019.05.010

--Sonjak V, Jacob KW, **Morais JA**, Rivera-Zengotita M, Spendiff S, Spake C, Taivassalo T, Chevalier S, HeppleRT. Fidelity of Reinnervation Modulates Susceptibility to Aging Muscle Impact in Elderly Women. *J Physiol.* 2019 Aug 1. doi: 10.1113/JP278261.

--Buckinx F, Marcangeli V, Carvalho LP, Dulac M, Boutros GH, Gouspillou G, Gaudreau P, **Morais JA**, Noirez P, Aubertin-Leheudre M. Initial Dietary Protein Intake Influence Muscle Function Adaptations in Older Men and Women Following High-Intensity Interval Training Combined with Citrulline. *Nutrients.* 2019 Jul 22;11(7). pii: E1685. doi: 10.3390/nu11071685

--Boutros GH, Jacob KW, Fulop T, Khalil A, Dionne I, Tessier D, Trutschnigg B, Kilgour RD, Vigano A, **Morais JA**. Energy utilization and fatigue in frail older women in relation to walking. *Adv Geriatr Med Res.* 2019;1:e190013. <https://doi.org/10.20900/agmr20190013>.

--Mate K, Abou-Sharkh A, **Morais JA**, Mayo N. Real-Time Auditory Feedback Induced Adaptation to Walking among Seniors using Heel2Toe Sensor: A Proof-of-Concept Study. *JMIR Rehabil Assist Technol.* 2019 Dec 11;6(2):e13889. doi: 10.2196/13889.

NESSIM, Sharon

--Boudville N, Johnson DW, Zhao J, Bieber BA, Pisoni RL, Piraino B, Bernardini J, **Nessim SJ**, Ito Y, Woodrow G, Brown F, Collins J, Kanjanabuch T, Szeto CC, Perl J. Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. *Nephrol Dial Transplant.* 2019 Dec 1;34(12):2118-2126

Paliouras, Miltiadis

--Sharif-Askari B, Doyon D, **Paliouras M**, Aloyz R. Bruton's tyrosine kinase is at the cross roads of metabolic adaptation in primary malignant human Lymphocytes. *Scientific Rep.* 2019. Jul 30; 9(1):11069.

--Nash C, Boufaied N, Badescu D, Wang YC, **Paliouras M**, **Trifiro M**, Ragoussis J, Thomson A. Genome-wide analysis of AR binding and transcriptomic analysis in mesenchymal subsets during prostate development. *Dis Model Mech.* 2019 Jul 25;12(7). pii: dmm039297. doi: 10.1242/dmm.039297.

Peters, Tricia

--**Peters TM**, Brazeau AS. Exercise in Pregnant Women with Diabetes. *Current Diabetes Reports.* 19(9):80, 2019. doi: 10.1007/s11892-019-1204-8.

Pantopoulos, Kostas

--Galaris D, Barbouti A. and **Pantopoulos K.** (2019) Iron homeostasis and oxidative stress: An intimate relationship, *Biochem. Biophys. Acta -Molecular Cell Research*, 1866, 118535.

--Wagner J, Fillebeen C, Haliotis T, Charlebois E, Katsarou A, Mui J, Vali H and **Pantopoulos K.** (2019) Mouse models of hereditary hemochromatosis do not develop early liver fibrosis in response to a high fat diet, *PLoS One*, 14, e0221455.

--Charlebois E, Fillebeen C and **Pantopoulos K.** (2019) Hepatocellular heme oxygenase 1 deficiency does not affect inflammatory hepcidin regulation in mice, *PLoS One*, 14, e0219835.

--Sung H. K, Song E, Jahng JWS, **Pantopoulos K** and Sweeney G. (2019) Iron induces insulin resistance in

cardiomyocytes via regulation of oxidative stress, *Scientific Reports*, 9, 4668.

--Fillebeen C, Charlebois E, Wagner J, Katsarou A, Mui J, Vali H, Garcia dos Santos D, Ponka P, Presley J and **Pantopoulos K**. (2019) Transferrin receptor 1 controls systemic iron homeostasis by fine-tuning hepcidin expression to hepatocellular iron load, *Blood*, 133, 344-355.

Pollak, Michael

--DuBois RN, **Pollak MN**. Cancer Prevention: A Message from the New Editors-in-Chief. *Cancer Prev Res (Phila)* 12(1):1-2, 2019.

--Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, **Pollak M**, Noer PR, Lorette J, Fazli L, Alag A, Meltzer P, Lau C, Conover CA, Oxvig C, Sorensen PH, Maris JM, Khan J, Mackall CL. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. *J Natl Cancer Inst*. 2019 Sep 1;111(9):970-982.

--*Uchenunu O, **Pollak M**, Topisirovic I, Hulea L. Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. *J Mol Endocrinol* 1;62(2):R83-R103, 2019.

--Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillesen S, von Moos R, **Pollak M**, Manetsch G, Strebel R, Cathomas R. Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (Meta-Pro): Phase 2 Pilot Study. *Clin Genitourin Cancer* S1558-7673(18)30814-0, 2019.

--Watts EL, Perez-Cornago A, Appleby PN, Albanes D, Ardanaz E, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chubb SAP, Cook MB, Deschasaux M, Donovan JL, English DR, Flicker L, Freedman ND, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Häggström C, Haiman C, Hamdy FC, Herberg S, Holly JM, Huang J, Huang WY, Johansson M, Kaaks R, Kubo T, Lane JA, Layne TM, Le Marchand L, Martin RM, Metter EJ, Mikami K, Milne RL, Morris HA, Mucci LA, Neal DE, Neuhaus ML, Oliver SE, Overvad K, Ozasa K, Pala V, Pernar CH, **Pollak M**, Rowlands MA, Schaefer CA, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Touvier M, Trichopoulou A, Tsilidis KK, Van Den Eeden SK, Weinstein SJ, Wilkens L, Yeap BB, Key TJ, Allen NE, Travis RC. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. *Int J Cancer*. 2019 Dec 15;145(12):3244-3256.

--Münch NS, Fang HY, Ingermann J, Maurer HC, Anand A, Kellner V, Sahn V, Wiethaler M, Baumeister T, Wein F, Einwächter H, Bolze F, Klingenspor M, Haller D, Kavanagh M, Lysaght J, Friedman R, Dannenberg AJ, **Pollak M**, Holt PR, Muthupalani S, Fox JG, Whary MT, Lee Y, Ren TY, Elliot R, Fitzgerald R, Steiger K, Schmid RM, Wang TC, Quante M. High-fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via IL8 and Alterations to the Gut Microbiome. *Gastroenterology* 157(2):492-506, 2019.

--*Papadopoli D, Boulay K, Kazak L, **Pollak M**, Mallette F, Topisirovic I, Hulea L. mTOR as a central regulator of lifespan and aging. *F1000Res*. 2019 Jul 2;8. pii: F1000 Faculty Rev-998. 2019.

--Hada M, Oh H, Pfeiffer RM, Falk RT, Fan S, Mullooly M, **Pollak M**, Geller B, Vacek PM, Weaver D, Shepherd J, Wang J, Fan B, Mahmoudzadeh AP, Malkov S, Herschorn S, Brinton LA, Sherman ME, Gierach GL. Relationship of circulating insulin-like growth factor-I and binding proteins 1-7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. *Breast Cancer Res* 21(1):81, 2019.

--Gui Y, Aguilar-Mahecha A, Krzemien U, Hosein A, Buchanan M, Lafleur J, **Pollak MN**, Ferrario C, Basik M. Metastatic breast carcinoma-associated fibroblasts have enhanced pro-tumorigenic properties related to increased IGF2 expression. *Clin Cancer Res*. 2019 Dec 1;25(23):7229-7242. 199.

--Molenaar RJ, van Hattum JW, Brummelhuis IS, Oddens JR, Savci-Heijink CD, Boevé ER, van der Meer SA, Witjes JF, **Pollak MN**, de Reijke TM, Wilmink JW. Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. *BMC Cancer*. 2019 Nov 21; 19(1):1133.

--Chan K, Robert F, Oertlin C, Kapeller-Libermann D, Avizonis D, Gutierrez J, Handly-Santana A, Doubrovin M, Park J, Schoepfer C, Da Silva B, Yao M, Gorton F, Shi J, Thomas CJ, Brown LE, Porco JA Jr, **Pollak M**, Larsson O, Pelletier J, Chio IIC. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. *Nat Commun*. 2019 Nov 13; 10(1):5151.

Richard, Stephane

--Litzler LC, A Zahn, A Meli, S Hébert, A-M Patenaude, SP Methot, A Sprumont, T Bois, D Kitamura, S Constantino, I King, CL Kleinman, **S Richard** and JM Di Noia. 2019. PRMT5 is essential for B cell development and germinal center dynamics. *Nat Commun* 10: 22

--Mersaoui SY, Z Yu, Y Coulombe, M Karam, FF Busatto, JY Masson, and **S. Richard** (2019). Arginine methylation of the DDX5 helicase RGG/RG motif by PRMT5 regulates resolution of RNA:DNA hybrids. *EMBO J* e100986.

--Guccione E and **S. Richard**. 2019. The regulation, functions, and clinical relevance of arginine methylation. *Nat Rev Mol Cell Biol*. Jul 26. doi: 10. 1038/s41580-019-0155-x.

--Qiao X, DI Kim, H Jun, Y Ma, AJ Knights, MJ Park, K Zhu, JH Lipinski, J Liao, Y Li, **S Richard**, SA Weinman, and J Wu (2019) *Endocrinology* pii:en. 2019-00504

--Wong TL, KY Ng, KV Tan, LH Chan, L Zhou, N Che, RL Hoo, TK Lee, **S Richard**, CM Lo, K Man, PL Khong, and S Ma (2019) *Hepatology* doi: 10. 1002/hep. 30923

Richards, Brent

--Baird DA, Evans DS, Kamanu FK, Gregory JS, Saunders FR, Giuraniuc CV, Barr RJ, Aspden RM, Jenkins D, Kiel DP, Orwoll ES, Cummings SR, Lane NE, Mullin BH, Williams FM, **Richards, JB**, Wilson SG, Spector TD, Faber BG, Lawlor DA, Grundberg E, Ohlsson C, Pettersson-Kymmer U, Capellini TD, Richard D, Beck TJ, Evans DM, Paternoster L, Karasik D, Tobias JH. (2019). Identification of novel loci associated with hip shape: a meta-analysis of genome-wide association studies. *J Bone Miner Res* [IF 6. 314]. 2019 Feb;34(2):241-251. doi: 10. 1002/jbmr. 3605. Epub 2018 Nov 26.

--Cerani A, Zhou S, Forgetta V, Morris JA, Trajanoska K, Rivadeneira F, Larsson SC, MichaelssonK, **Richards, JB**. 2019. Genetic predisposition to increased serum calcium, bone mineral density, and fracture risk in individuals with normal calcium levels: mendelian randomisation study. *BMJ* 2019;366:14410, doi. org/10. 1136/bmj. 1441

--D Manousaki, **JB Richards**. Role of vitamin D in disease through the lens of Mendelian randomization. *International Journal of Epidemiology* [IF: 8. 36]. 2019 Oct 1;48(5):1435-1437. doi: 10. 1093/ije/dy183.

--Harroud A, Morris JA, Forgetta V, Mitchell R, Smith GD, Sawcer S, **Richards, JB**. Effect of age at puberty on risk of multiple sclerosis: A Mendelian randomization study. *Neurology* [IF: 8. 055], 2019 Apr 16. 92(16):e1803-e1810. doi: 10. 1212/WNL. 0000000000007325. Highlighted with an Editorial: "Leveraging human genetics to inform intervention strategies for multiple sclerosis. " *Neurology*, 2019. "

--Johansson M, Carreras-Torres R, Scelo G, Purdue MP, Mariosa D, Muller DC, Timpson NJ, Haycock PC, Brown KM, Wang Z, Ye Y, Hofmann JN, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Garnier JG, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Radojevic-Skodric S, Ognjanovic S, Foretova L, Holcatova I, Janout V, Mates D, Mukeriy A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Benhamou S, Cancel-Tassin G, Cussenot O, Weiderpass E, Ljungberg B, Tumkur Sitaram R, Häggström C, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Andreotti G, Beane Freeman LE, Koutros S, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Wilson KM, Gaziano JM, Sesso HD, Freedman

ND, Parker AS, Eckel-Passow JE, Huang WY, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, The BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Lathrop GM, Deleuze JF, Gunter M, McKay JD, Wu X, Houlston RS, Chanock SJ, Relton C, **Richards, JB**, Martin RM, Davey Smith G, Brennan P. (2019). The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. *PLoS Med.* [IF: 11.675]. 2019 Jan 3;16(1):e1002724. doi: 10.1371/journal.pmed.1002724. eCollection 2019 Jan.

--**Richards B**, Kiel DP 2019. Preface to the BONE special issue on skeletal genomics. *Bone* [IF: 4.455] 2019 Sep;126:1. doi: 10.1016/j.bone.2019.05.030. Epub 2019 May 25.

Rosenblatt, David

--Ruetz M, Campanello GC, McDevitt L, Yokom AL, Watkins D, **Rosenblatt DS**, Ohi MD, Southworth DR, Banerjee R. Allosteric regulation of oligomerization by a B₁₂ trafficking G-protein is corrupted in methylmalonic aciduria. *Cell Chem Biol* 26:960-969, 2019.

--Wehbe Z, Behringer S, Altabi KI, Watkins D, **Rosenblatt DS**, Spierkerkoetter U, Tucci S. The emerging role of the mitochondrial fatty acid synthase (mtFSII) in the regulation of energy metabolism. *Biochim Biophys Acta Mol Cell Biol Lipids* 1864:1629-1643, 2019.

--Abdrabo LS, Watkins D, Wang SR, Lafond-Lapalme J, Riviere JB, **Rosenblatt DS**. Genome and RNA sequencing in patients with methylmalonic aciduria of unknown cause. *Genet Med* doi:10.1038/s41436-019-0640-9, 2019.

Roshdy, Osama

--Ghazawi FM, Le M, Lagacé F, Cyr J, Alghazawi N, Zubarev A, Roy SF, Rahme E, Netchiporouk E, **Roshdy O**, Glassman SJ, Sasseville D, Litvinov IV. Incidence, Mortality, and Spatiotemporal Distribution of Cutaneous Malignant Melanoma Cases Across Canada. *J Cutan Med Surg.* 2019 Jul/Aug;23(4):394-412. doi: 10.1177/1203475419852048. Epub 2019 May 27.

--Tsang M, Le M, Ghazawi FM, Cyr J, Alakel A, Rahme E, Lagacé F, Netchiporouk E, Moreau L, Zubarev A, **Roshdy O**, Glassman SJ, Sasseville D, Popradi G, Litvinov IV. Multiple myeloma epidemiology and patient geographic distribution in Canada: A population study. *Cancer.* 2019 Jul 15;125(14):2435-2444. doi: 10.1002/cncr.32128. Epub 2019 Apr 5.

--Muntyanu A, Redpath M, **Roshdy O**, Jfri A. Idiopathic Atrophoderma of Pasini and Pierini: Case report and literature review. *Clin Case Rep.* 2018 Dec 18;7(2):258-263. doi: 10.1002/ccr3.1958. eCollection 2019 Feb.

--Ghazawi FM, Le M, Cyr J, Netchiporouk E, Rahme E, Alakel A, Zubarev A, Powell M, Moreau L, **Roshdy O**, Glassman SJ, Sasseville D, Popradi G, Litvinov IV. Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario. *Cancer.* 2019 Jun 1;125(11):1886-1897. doi: 10.1002/cncr.32034. Epub 2019 Feb 27.

Sakr, Lama

--Frohlich M, Wang H, **Sakr L**. Sarcoid-like Reaction Discovered on EBUS-TBNA of Intrathoracic Lymph Nodes During Immunotherapy for Metastatic Melanoma. *J Immunother.* Publish ahead of print [epub September 24 2019].

Schiffrin, Ernesto L.

--Caillon A, Paradis P, **Schiffrin EL**. Role of immune cells in hypertension. *Brit J Pharmacol.* 2019;176(12):1818-1828. doi:10.1111/bph.14427.

--Iulita MF, Duchemin S, Vallerand D, Barhoumi T, Alvarez F., Istomine R, Laurent C, Youwakim J, Paradis P,

Arbour N, Piccirillo CA, **Schiffrin EL**, Girouard H. CD4+ Regulatory T lymphocytes prevent impaired cerebral blood flow in angiotensin II-induced hypertension. *J Am Heart Assoc.* 2019;8:e009372. DOI: 10.1161/JAHA.118.009372.

--Higaki A, Caillon A, Paradis P, **Schiffrin EL**. Innate and Innate-like Immune System in Hypertension and Vascular Injury. *Current Hypert Rep.* 2019;21:4. DOI: 10.1007/s11906-019-0907-1. PMID: 30659373.

--Calhoun DA, **Schiffrin EL**, Flack JM. Resistant Hypertension: An Update. Editorial. *Amer J Hypert.* , 2019;31:1-3. doi:10.1093/ajh/hpy156.

--**Schiffrin EL**. New blood pressure cut-offs, prevalence of hypertension and control, and mood disorders: Are patients benefiting from lower cut-offs for defining hypertension? Editorial. *Eur Heart J.* 2019;40:739–742. <https://doi.org/10.1093/eurheartj/ehy891>.

--Huo K-G, Richer C, Berillo O, Mahjoub N, Fraulob-Aquino JC, Barhoumi T, Ouerd S, Coelho SC, Sinnott D, Paradis P, **Schiffrin EL**. miR-431-5p knockdown protects against angiotensin II-induced hypertension and vascular injury. *Hypertension.* 2019;73:1007–1017. DOI: 10.1161/HYPERTENSIONAHA.119.12619.

--Zack R, Okunade O, Olson E, Salt M, Amodeo C, Anchala R, Berwanger O, Campbell N, Chia Y-C, Damasceno A, Do TNP, Tamdja Dzudie A, Fiuza M, Mirza F, Nitsch D, Ogedegbe G, Podpalov V, **Schiffrin EL**, Carneiro AV, Lamptey P. Improving Hypertension Outcome Measurement in Low- And Middle-Income Countries. *Hypertension.* 2019; 73:990–997. Doi: 10.1161/HYPERTENSIONAHA.118.11916.

--Carcel C, Neal B, Rodgers K, Oparil S, Narkiewicz K, Wang J, **Schiffrin EL**, Azizi MP, Poulter N, Chalmers. Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment resistant hypertension: the SPIRIT study. *J Hypertens.* 2019;37:2216-2224. doi: 10.1097/HJH.0000000000002184.

--Jurrissen TJ, Grunewald ZI, Woodford ML, Winn NC, Ball JR, Smith TN, Wheeler A, Rawlings AL, Staveley-O'Carroll KF, Ji Y, Fay WP, Paradis P, **Schiffrin EL**, Vieira-Potter VJ, Fadel PJ, Martinez-Lemus LA, Padilla J. Overproduction of endothelin-1 impairs glucose tolerance but does not promote visceral adipose tissue inflammation or limit metabolic adaptations to exercise. *Amer J Physiol (Endo Metab).* *Am J Physiol Endocrinol Meta* 317: E548–E558, 2019. doi: 10.1152/ajpendo.00178.2019.

--Khan N, Bell A, Berg A, Campbell A, Kacorowski J, Rabi D, **Schiffrin EL**, Tsuyuki RT. A Call to Action to Implement Prescribing Authority to Pharmacists for Hypertension Management. *Can Pharm J (Ott).* 2019; DOI: 10.1177/1715163519866144.

--**Schiffrin EL**, Engert JC. Periodontitis and hypertension: causally linked by immune mechanisms. Editorial. *Eur Heart J.* 2019;40:3471-3473. Doi: 10.1093/eurheartj/ehz729.

--Grunewald ZI, Jurrissen TJ, Woodford ML, Ramirez-Perez FI, Park LK, Pettit-Mee R, Ghiarone T, Brown SM, Morales-Quinones M, Ball JR, Staveley-O'Carroll KF, Aroor AR, Fadel PJ, Paradis P, **Schiffrin EL**, Bender SB, Martinez-Lemus LA, Padilla J. Chronic elevation of endothelin-1 alone may not be sufficient to impair endothelium-dependent relaxation. *Hypertension.* 2019; 74:1409-1419. DOI:10.1161/HYPERTENSIONAHA.119.13676.

Schwartz, Blair

--Simard C, **Schwartz BC**. An Electrocardiogram-Based Diagnosis of Coma *Am J Med.* 2019 Oct;132(10):e735-e736.

Schwartz, Jesse

--Blumenthal KG, Li Y, Hsu JT, Wolfson AR, Berkowitz DN, Carballo VA, **Schwartz JM**, Marquis KA, Elshaboury R, Gandhi RG, Lambl BB, Freeley MM, Gruszecki A, Wickner PG, Shenoy ES. Outcomes from an

inpatient beta-lactam allergy guideline across a large US health system. *Infect Control Hosp Epidemiol*. 2019 May;40(5):528-535.

Sebag, Igal

--Habib G, Lancellotti P, Erba PA, Sadeghpour A, Meshaal M, Sambola A, Furnaz S, Citro R, Ternacle J, Donal E, Cosyns B, Popescu B, Iung B, Prendergast B, Laroche C, Tornos P, Pazdernik M, Maggioni A, Gale CP; EURO-ENDO Investigators (including **Sebag IA**). The ESC-EORP EURO-ENDO (European Infective Endocarditis) Registry. *Eur Heart J Qual Care Clin Outcomes* 2019; 5(3):202-207.

--Asnani A, Shi X, Farrell L, Lall R, **Sebag IA**, Plana JC, Gerszten RE, Scherrer-Crosbie M. Changes in Citric Acid Cycle and Nucleoside Metabolism Are Associated with Anthracycline Card Cardiotoxicity in Patients with Breast Cancer. *Journal of Cardiovascular Translational Research* 2019. *J Cardiovasc Transl Res* 2019; Jul 5. doi: 10.1007/s12265-019-09897-y. [Epub ahead of print].

--Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, Popescu BA, Prendergast B, Tornos P, Sadeghpour A, Oliver L, Vaskelyte JJ, Sow R, Axler O, Maggioni AP, Lancellotti P; EURO-ENDO Investigators (including **Sebag IA**). Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. *Eur Heart J*. 2019; 40(39):3222-32.

Semret, Makeda

--Jacobs J, Hardy L, **Semret M**, Lunguya O, Phe T, Affolabi D, Yansouni C, Vandenberg O. Diagnostic Bacteriology in District Hospitals in Sub-Saharan Africa: At the Forefront of the Containment of Antimicrobial Resistance. *Front Med (Lausanne)*. 2019 Sep 23;6:205. doi: 10.3389/fmed.2019.00205. eCollection 2019. Review. PMID: 31608280

--LeBlanc JJ, ElSherif M, Ye L, MacKinnon-Cameron D, Ambrose A, Hatchette TF, Lang ALS, Gillis HD, Martin I, Demczuk W, Andrew MK, Boivin G, Bowie W, Green K, Johnstone J, Loeb M, McCarthy AE, McGeer A, **Semret M**, Trottier S, Valiquette L, Webster D, McNeil SA. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). *Vaccine*. 2019 Aug 23;37(36):5466-5473. doi: 10.1016/j.vaccine.2019.05.003. Epub 2019 Jul 23.

--**Semret M**, Haraoui LP. Antimicrobial Resistance in the Tropics. *Infect Dis Clin North Am*. 2019 Mar;33(1):231-245. doi: 10.1016/j.idc.2018.10.009. Review.

--Mulpuru S, Li L, Ye L, Hatchette T, Andrew MK, Ambrose A, Boivin G, Bowie W, Chit A, Dos Santos G, ElSherif M, Green K, Haguinet F, Halperin SA, Iburguchi B, Johnstone J, Katz K, Langley JM, LeBlanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Powis J, Richardson D, **Semret M**, Shinde V, Smyth D, Trottier S, Valiquette L, Webster D, McNeil SA; Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN). Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. *Chest*. 2019 Jan;155(1):69-78. doi: 10.1016/j.chest.2018.10.044.

Suissa, Samy

--Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, Ost DE, Punjabi NM, Schatz M, Smyth AR, Stewart PW, **Suissa S**, Adjei AA, Akdis CA, Azoulay E, Bakker J, Ballas ZK, Bardin PG, Barreiro E, Bellomo R, Bernstein JA, Brusasco V, Buchman TG, Chokroverty S, Collop NA, Crapo JD, Fitzgerald DA, Hale L, Hart N, Herth FJ, Iwashyna TJ, Jenkins G, Kolb M, Marks GB, Mazzone P, Moorman JR, Murphy TM, Noah TL, Reynolds P, Riemann D, Russell RE, Sheikh A, Sotgiu G, Swenson ER, Szczesniak R, Szymusiak R, Teboul JL, Vincent JL. Control of Confounding and Reporting of Results in Causal Inference Studies: Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. *Ann Am Thorac Soc*. 2019

Jan;16(1):22-28.

--Lin HD, Lai CL, Dong YH, Tu YK, Chan KA, **Suissa S**. Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study. *Drugs Real World Outcomes*. 2019;6(3):93-104.

--Loo SY, Vutcovici M, Bitton A, Lakatos PL, Azoulay L, **Suissa S**, Brassard P. Risk of malignant cancers in inflammatory bowel disease. *J Crohns Colitis*. 2019 Sep 27;13(10):1302-1310.

--Montastruc F, Nie R, Loo S, Dell'Aniello S, Micallef J, **Suissa S**, Renoux C. Association of aripiprazole with the risk for psychiatric hospitalization. Self-harm or suicide. *JAMA Psychiatry* 2019;76(4):409-417.

--Platt RW, Platt R, Brown JS, Henry DA, Klungel OH, **Suissa S**. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. *Pharmacoepidemiol Drug Saf*. 2019 Jan 15 (epub ahead of print).

--Ripamonti E, Azoulay L, **Suissa S**, Platt R. A systematic review of observational studies of the association between pioglitazone and bladder cancer. *Diabetic Medicine* 2019 Jan;36():22-35.

--Schneeweiss S, **Suissa S**. Discussion of Schuemie et al: A plea to stop using the case-control design in retrospective database studies. *Stat Med*. 2019 Sep 30;38(22):4209-4212.

--Simon TA, Boers M, Hochberg M, Baker N, Skovron ML, Ray N, Singhal S, **Suissa S**, Gomez-Caminero A. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. *Arthritis Res Ther*. 2019 Nov 8;21(1):228.

--**Suissa S**, Ariel A. Triple therapy trials in COPD: only for the right patient. *EurRespir J* 2019 18;53(4).

--**Suissa S**. Improving the Efficiency of Randomized Trials: The DYNAGITO Example. *COPD*. 2019 Dec 3:1-3.

--**Suissa S**. Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias? *EurRespir J*. 2019 Feb;53(2). Epub ahead of print.

--Sultana J, Trotta F, Addis A, Brown JS, Gil M, Menniti-Ippolito F, Milozzi F, **Suissa S**, Trifirò G. Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. *Drug Saf*. 2019 Oct 22. doi: 10.1007/s40264-019-00871-w. [Epub ahead of print].

Tagalakis, Vicky

--Cafaro T, Simard C*, **Tagalakis V**, Koolian M. Delayed time to emergency hip surgery in patients taking oral anticoagulants. *Thrombosis Research*. 2019;184:110-114.
-e581.

--Klil-Drori AJ, Prajapati D, Liang Z, Wang M, Toupin D, Alothman L, Lang E, Suryanarayan D, **Tagalakis V**. External Validation of ASPECT (Algorithm for Suspected Pulmonary Embolism Confirmation and Treatment). *Medical Care* 2019 Aug;57(8):e47-e52.

--Carrier M, Abou-Nassar K, Mallick R, **Tagalakis V**, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS. AVERT Investigators. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. *N Engl J Med* 2019 Feb 21;380(8):711-719.

--**Tagalakis V**. Sex may matter when it comes to the presenting location of deep vein thrombosis. *Thrombosis Research* 2019 Jan;173:164-165.

Tamilia, Michael

--Larouche V, Pusztaszeri MP, Filimon S, Payne R, Hier M, **Tamília M**. Preoperative prediction of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: a Canadian single-Centre experience. *J Otolaryngol Head Neck Surg*. 2020 Jan 2;49(1):1. doi: 10.1186/s40463-019-0397-9.

--Radi S, **Tamília M**. Adrenocortical carcinoma: an ominous cause of hirsutism. *BMJ Case Rep*. 2019 Dec 30;12(12). pii: e232547. doi: 10.1136/bcr-2019-232547.

--You E, Mascarella MA, Al Jassim A, Forest VI, Hier MP, **Tamília M**, Pusztaszeri M, Payne RJ. Prevalence and aggressiveness of papillary thyroid carcinoma in surgically-treated graves' disease patients: a retrospective matched cohort study. *J Otolaryngol Head Neck Surg*. 2019 Aug 28;48(1):40. doi: 10.1186/s40463-019-0364-5.

Therrien, Judith

--Bottega N, Malhamé I, Guo L, Ionescu-Ittu R, **Therrien J**, Marelli A. Secular trends in pregnancy rates, delivery outcomes, and related health care utilization among women with congenital heart disease. *Congenital Heart Disease*. *Congenital Heart Dis*. 2019 Sep;14(5):735-744. doi: 10.1111/chd.12811. Epub 2019.

--Cohen S, Gurvitz MZ, Beauséjour-Ladouceur V, Lawler PR, **Therrien J**, Marelli AJ. Cancer Risk in Congenital Heart Disease - What Is the Evidence? *Canadian Journal of Cardiology*, 35:12, 1750-1761, 2019.

--Mongeon FP, Ben Ali W, Khairy P, Bouhout I, **Therrien J**, Wald RM, Dallaire F, Bernier PL, Poirier N, Dore A, Silversides C, Marelli A. Pulmonary Valve Replacement for Pulmonary Regurgitation in Adults With Tetralogy of Fallot: A Meta-analysis - A Report for the Writing Committee of the 2019 Update of the Canadian Cardiovascular Society Guidelines for the Management of Adults with Congenital Heart Disease. *Canadian Journal of Cardiology*, 35:12, 1772-1783, 2-019.

--**Therrien J**, Marelli A. Congenital Heart Disease in the Adults. Chapter 61. *Goldman-Cecil Textbook* 26, 2019.

Thombs Brett D

--Birtwhistle R, Morissette K, Dickinson JA, Reynolds DL, Avey MT, Reyes Domingo F, Rodin R, **Thombs BD***, Canadian Task Force on Preventive Health Care. Recommendations on screening adults for asymptomatic thyroid dysfunction in primary care. *CMAJ*. 2019; 191:E1274-1280.

--Pépin M, Kwakkenbos L, Carrier M-E, Peláez S, El-Baalbaki G, Malcarne VL, **Thombs BD***, Scleroderma Patient-centered Network (SPIN) Support Group Project Advisory Team. Reasons for attending support groups and organizational preferences: a replication study using the North American Scleroderma Support Group Survey. *J Scleroderma Relat Disord*. 2019;4(3):173-186.

--Tao L, Fedoruk C, Turner K, Cumin J, Carrier M-E, Carboni-Jiménez A, Pépin M, Kwakkenbos L, **Thombs BD***, SPIN Patient Advisory Board. The Scleroderma Research Topics Survey for patients and health care professionals: a Scleroderma Patient-centered Intervention Network (SPIN) project. *J Scleroderma Relat Disord*. 2019;4(3):165-172.

--Milette K, **Thombs BD***, Maiorino K, Nielson WR, Körner A, Peláez S. Challenges and strategies for coping with scleroderma: implications for a scleroderma-specific self-management program. *Disabil Rehabil*. 2019;41(21):2506-2515.

--Ioannidis JPA, **Thombs BD**. A user's guide to inflated and manipulated impact factors. *Eur J Clin Invest*. 2019;49:e13151.

--Gates M, Pillay J, Thériault G, Limburg H, Grad R, Klarenbach S, Korownyk C, Reynolds D, Riva J, **Thombs BD**, Kline G, Leslie WD, Courage S, Vandermeer B, Featherstone R, Hartling L. Screening to prevent fragility fractures among adults 40 years and older in primary care: protocol for a systematic review. *Syst Rev*.

2019;8:216

--Moynihan R, Bero L, Hill S, Johansson M, Lexchin J, MacDonald H, Mintzes B, Pearson C, Stavdal A, Stegenga J, **Thombs BD**, Thornton H, Vandvik P, Wieseler B, Godlee F. Pathways to independence: towards producing and using trustworthy evidence. *BMJ*. 2019;367:16576.

--Delisle VC, Gumuchian ST, El-Baalbaki G, Körner A, Malcarne VL, Peláez S, Carrier M-E, Pépin M, **Thombs BD***, Scleroderma Support Group Project Advisory Team. Training and support needs of scleroderma support group facilitators: the North American Scleroderma Support Group Facilitators Survey. *Disabil Rehabil*. 2019;41(20):2477-2482.

--Azar M, Riehm K, Saadat N, Sanchez T, Chiovitti M, Qi L, Rice DB, Levis B, Fedoruk C, Levis AW, Kloda LA, Kimmelman J, Benedetti A, **Thombs BD***. Journal registration policies and association with prospective registration in published randomized trials of non-regulated healthcare Interventions: a cross-sectional study. *JAMA Intern Med*. 2019;179(5):624-632.

--Bashir NY, Moore JE, Buckland D, Rodrigues M, Tonelli M, **Thombs BD**, Bell NR, Isaranuwatthai W, Peng T, Shilman DM, Straus SE. Are patient educational materials on cancer screening more effective when co-created with patients? A qualitative interview study and randomized controlled trial. *Curr Oncol*. 2019;26(2):124-136.

--Gumuchian ST, Delisle VC, Kwakkenbos L, Pépin M, Carrier M-E, Malcarne CL, Peláez S, El-Baalbaki G, **Thombs BD***, Scleroderma Support Group Project Advisory Team. Reasons for attending support groups and organizational preferences: the European Scleroderma Support Group Members Survey. *Disabil Rehabil*. 2019;41(8):974-982.

--Turner KA, Rice DB, Carboni-Jiménez A, Boruff J, **Thombs BD***. Effects of training and support programs for leaders of illness-based support groups: commentary and updated evidence. *Syst Rev*. 2019;8:67.

--Rice DB, **Thombs BD***. Support groups in scleroderma. *Current Rheumatol Rep*. 2019;21(4):9.

--Salameh J-P, McInnes MDF, Moher D, **Thombs BD**, McGrath TA, Frank R, Sharifabadi AD, Kraaijpoel N, Levis B, Bossuyt PM. Completeness of reporting of systematic reviews of diagnostic test accuracy based on the PRISMA-DTA reporting guideline. *Clin Chem*. 2019;65(2):291-301.

--Hersi M, Traversy G, **Thombs BD**, Beck A, Skidmore A, Groulx S, Lang E, Reynolds DL, Wilson B, Bernstein SL, Selby P, Johnson-Obaseki S, Manuel D, Pakhale S, Pesseau J, Courage S, Hutton B, Shea BJ, Welch V, Morrow M, Little J, Stevens A. Effectiveness of stop smoking interventions among adults: protocol for an overview of systematic reviews and an updated systematic review. *Syst Rev*. 2019;8:28.

Trifiro, Mark

--Chowdhury S, Beitel LK, Lumbroso R, Purisima EO, **Trifiro M**, **Paliouras M**. A targeted bivalent androgen receptor-binding compound for prostate cancer therapy. *Horm Cancer*. 2019 Feb;10(1):24-35. doi: 10.1007/s12672-018-0353-6. Epub 2018 Dec 18.

Vedel, Isabelle

--**Vedel I**, Kaur N, Hong QN, El Sherif R, Khanassov V, Godard-Sebillotte C, Sourial N, Yang XQ, Pluye P. Why and how to use mixed methods in primary health care research. *Fam Pract*. 2019 May 23;36(3):365-368. doi: 10.1093/fampra/cmz127. No abstract available.

--Hong QN, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, Gagnon MP, Griffiths F, Nicolau B, O'Cathain A, Rousseau MC, **Vedel I**. Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study. *J Clin Epidemiol*. 2019 Jul;111:49-59.e1. doi: 10.1016/j.jclinepi.2019.03.008. Epub 2019 Mar 22.

--Kaur N, **Vedel I**, El Sherif R, Pluye P. Practical mixed methods strategies used to integrate qualitative and quantitative methods in community-based primary health care research. *Fam Pract*. 2019 Oct 8;36(5):666-671. doi: 10.1093/fampra/cmz010.

--Godard-Sebillotte C, Karunanathan S, **Vedel I**. Difference-in-differences analysis and the propensity score to estimate the impact of non-randomized primary care interventions. *Fam Pract*. 2019 Mar 20;36(2):247-251. doi: 10.1093/fampra/cmz003. No abstract available.

--Hamzeh J, Pluye P, Bush PL, Ruchon C, **Vedel I**, Hudon C. Towards an assessment for organizational participatory research health partnerships: A systematic mixed studies review with framework synthesis. *Eval Program Plann*. 2019 Apr;73:116-128. doi: 10.1016/j.evalprogplan.2018.12.003. Epub 2018 Dec 11.

Yu, Oriana

--Pradhan R, Yin H, **Yu OHY**, Azoulay L. The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer among Patients with Type 2 Diabetes: A Population-Based Cohort Study. *Drug Saf*. 2019 Dec 14. doi: 10.1007/s40264-019-00892-5. [Epub ahead of print]

--Loo SY, Azoulay L, Nie R, Dell'Aniello S, **Yu OHY**, Renoux C. . Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study. *American Journal of Medicine*. 2019 132(9):1069-1077. doi: 10.1016/j.amjmed.2019.03.022.

--Santella C, Renoux C, Yin H, **Yu OHY**, Azoulay L. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism. *Am J Epidemiol*. 2019 Sep 1;188(9):1666-1673. doi: 10.1093/aje/kwz138.

--Filion KB, **Yu OH**. Sodium-Glucose Cotransporter-2 Inhibitors and Severe Urinary Tract Infections: Reassuring Real-World Evidence. *Ann Intern Med*. 2019 Jul 30. doi: 10.7326/M19-1950. [Epub ahead of print].

--Filion KB, Douros A, Azoulay L, Yin H, **Yu OH**, Suissa S. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. *Br J Clin Pharmacol*. 2019 Oct;85(10):2378-2389. doi: 10.1111/bcp.14056. Epub 2019 Jul 31.

--Abrahami D, Douros A, Yin H, **Yu OH**, Azoulay L. Sodium-glucose co-transporter 2 inhibitors and the risk of fractures in patients with type 2 diabetes. *Diabetes Care*. 2019 Sep; 42(9): e150-e152.

--Renoux C, Azoulay L, Dell'Aniello S, **Yu OHY**. The Reply. *Am J Med*. 2019 Oct;132(10):e749. doi: 10.1016/j.amjmed.2019.06.010. Epub 2019 Jul 26.

--Douros A, Rouette J, Yin H, **Yu OHY**, **Filion KB**, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes. *Diabetes Care* 2019 Aug;42(8):1496-1503.

--Douros A, Dell'Aniello S, **Yu OHY**, Suissa S. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study. *Diabetes Obes Meta*. 2020 Feb;22(2):254-262. doi: 10.1111/dom.13893. Epub 2019 Nov 3.

7. APPENDIX A. DIVISIONAL REPORTS